

The Impact of Mutations in SARS-CoV-2 Spike on Viral

Cell

182, 1284-1294.e9

DOI: [10.1016/j.cell.2020.07.012](https://doi.org/10.1016/j.cell.2020.07.012)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ACE2 enhance viral infection or viral infection aggravate the underlying diseases. Computational and Structural Biotechnology Journal, 2020, 18, 2100-2106.	4.1	6
2	Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nature Protocols, 2020, 15, 3699-3715.	12.0	291
3	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell, 2020, 183, 1024-1042.e21.	28.9	1,195
4	Chemosensory Dysfunction in COVID-19: Integration of Genetic and Epidemiological Data Points to D614G Spike Protein Variant as a Contributing Factor. ACS Chemical Neuroscience, 2020, 11, 3180-3184.	3.5	59
5	Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. Trends in Immunology, 2020, 41, 1006-1022.	6.8	79
6	Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends in Immunology, 2020, 41, 1100-1115.	6.8	794
7	Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. Cell Host and Microbe, 2020, 28, 867-879.e5.	11.0	316
8	No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. Nature Communications, 2020, 11, 5986.	12.8	260
9	Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. Science Translational Medicine, 2020, 12, .	12.4	203
10	The Potential Role of Osteopontin and Furin in Worsening Disease Outcomes in COVID-19 Patients with Pre-Existing Diabetes. Cells, 2020, 9, 2528.	4.1	22
11	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduction and Targeted Therapy, 2020, 5, 282.	17.1	149
12	Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. Frontiers in Molecular Biosciences, 2020, 7, 605236.	3.5	159
13	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature, 2020, 588, 682-687.	27.8	1,346
14	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science, 2020, 370, 1464-1468.	12.6	808
15	Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. Journal of Virology, 2020, 94, .	3.4	116
16	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nature Reviews Immunology, 2020, 20, 727-738.	22.7	107
17	Genetic Spectrum and Distinct Evolution Patterns of SARS-CoV-2. Frontiers in Microbiology, 2020, 11, 593548.	3.5	44
18	Evolutionary Analysis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reveals Genomic Divergence with Implications for Universal Vaccine Efficacy. Vaccines, 2020, 8, 591.	4.4	3

#	ARTICLE	IF	CITATIONS
19	High-Density Amplicon Sequencing Identifies Community Spread and Ongoing Evolution of SARS-CoV-2 in the Southern United States. <i>Cell Reports</i> , 2020, 33, 108352.	6.4	38
20	The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. <i>Frontiers in Immunology</i> , 2020, 11, 576622.	4.8	317
21	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. <i>Cell</i> , 2020, 183, 1367-1382.e17.	28.9	420
22	Prevalence of Chemosensory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2944-2961.	3.5	189
23	Low genetic diversity may be an Achilles heel of SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24614-24616.	7.1	94
24	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020, 370, 950-957.	12.6	504
25	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. <i>Cell</i> , 2020, 183, 1013-1023.e13.	28.9	227
26	Profiling and characterization of SARS-CoV-2 mutantsâ€™ infectivity and antigenicity. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 185.	17.1	33
27	A genetic barcode of SARS-CoV-2 for monitoring global distribution of different clades during the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2020, 100, 216-223.	3.3	43
28	Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing. <i>Clinical Infectious Diseases</i> , 2021, 73, e2946-e2951.	5.8	647
29	Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection. <i>Neuroscientist</i> , 2021, 27, 582-603.	3.5	238
30	Infectivity of SARS-CoV-2: there Is Something More than D614G?. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 574-577.	4.1	44
31	SARS-CoV-2 Spike Alterations Enhance Pseudoparticle Titers and Replication-Competent VSV-SARS-CoV-2 Virus. <i>Viruses</i> , 2020, 12, 1465.	3.3	35
32	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). <i>Frontiers in Immunology</i> , 2020, 11, 571481.	4.8	48
33	COVID-19: Coronavirus Vaccine Development Updates. <i>Frontiers in Immunology</i> , 2020, 11, 602256.	4.8	143
34	Multiple Introductions Followed by Ongoing Community Spread of SARS-CoV-2 at One of the Largest Metropolitan Areas of Northeast Brazil. <i>Viruses</i> , 2020, 12, 1414.	3.3	47
35	Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. <i>MAbs</i> , 2020, 12, 1854149.	5.2	126
36	Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis. <i>Nature Communications</i> , 2020, 11, 6272.	12.8	183

#	ARTICLE	IF	CITATIONS
37	The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection. International Journal of Molecular Sciences, 2020, 21, 9309.	4.1	27
38	Recent updates on COVID-19: A holistic review. Heliyon, 2020, 6, e05706.	3.2	16
39	Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal. Emerging Microbes and Infections, 2020, 9, 2488-2496.	6.5	20
40	Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2. International Immunopharmacology, 2021, 90, 107172.	3.8	23
41	Phylogenetic analysis of SARS-CoV-2 in the first few months since its emergence. Journal of Medical Virology, 2021, 93, 1722-1731.	5.0	29
42	Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. Genomics, 2021, 113, 1221-1232.	2.9	126
43	Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity. Briefings in Bioinformatics, 2021, 22, 1239-1253.	6.5	99
44	Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochemical and Biophysical Research Communications, 2021, 538, 192-203.	2.1	165
45	High Prevalence of SARS-CoV-2 Genetic Variation and D614G Mutation in Pediatric Patients With COVID-19. Open Forum Infectious Diseases, 2021, 8, ofaa551.	0.9	26
46	N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects. Journal of Clinical Immunology, 2021, 41, 335-344.	3.8	17
47	Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. Human Vaccines and Immunotherapeutics, 2021, 17, 1635-1649.	3.3	14
48	Engineered trimeric ACE2 binds viral spike protein and locks it in a Three-up conformation to potently inhibit SARS-CoV-2 infection. Cell Research, 2021, 31, 98-100.	12.0	76
49	Host-directed editing of the SARS-CoV-2 genome. Biochemical and Biophysical Research Communications, 2021, 538, 35-39.	2.1	80
50	The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design. Biochemical and Biophysical Research Communications, 2021, 538, 104-107.	2.1	85
51	Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. Biochemical and Biophysical Research Communications, 2021, 538, 108-115.	2.1	79
52	An updated and comprehensive review of the antiviral potential of essential oils and their chemical constituents with special focus on their mechanism of action against various influenza and coronaviruses. Microbial Pathogenesis, 2021, 152, 104620.	2.9	106
53	Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host and Microbe, 2021, 29, 44-57.e9.	11.0	937
54	Nanozyme chemiluminescence paper test for rapid and sensitive detection of SARS-CoV-2 antigen. Biosensors and Bioelectronics, 2021, 173, 112817.	10.1	195

#	ARTICLE	IF	CITATIONS
55	COVID-19: The Effect of Host Genetic Variations on Host-Virus Interactions. Journal of Proteome Research, 2021, 20, 139-153.	3.7	14
56	Structural basis of severe acute respiratory syndrome coronavirus 2 infection. Current Opinion in HIV and AIDS, 2021, 16, 74-81.	3.8	7
57	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. Biotechnology and Biotechnological Equipment, 2021, 35, 74-102.	1.3	13
58	Spike Glycoprotein and Host Cell Determinants of SARS-CoV-2 Entry and Cytopathic Effects. Journal of Virology, 2021, 95, .	3.4	70
59	SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay. Emerging Microbes and Infections, 2021, 10, 51-65.	6.5	33
62	A facile chemoenzymatic synthesis of SARS-CoV-2 glycopeptides for probing glycosylation functions. Chemical Communications, 2021, 57, 6804-6807.	4.1	10
63	Ultra-large-scale ab initio quantum chemical computation of bio-molecular systems: The case of spike protein of SARS-CoV-2 virus. Computational and Structural Biotechnology Journal, 2021, 19, 1288-1301.	4.1	21
64	Single point mutations can potentially enhance infectivity of SARS-CoV-2 revealed by <i>in silico</i> affinity maturation and SPR assay. RSC Advances, 2021, 11, 14737-14745.	3.6	17
65	AutoVEM2: A flexible automated tool to analyze candidate key mutations and epidemic trends for virus. Computational and Structural Biotechnology Journal, 2021, 19, 5029-5038.	4.1	4
67	How strong is the evidence that it is possible to get SARS-CoV-2 twice? A systematic review. Reviews in Medical Virology, 2021, 31, 1-12.	8.3	7
68	The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization. Journal of Biological Chemistry, 2021, 296, 100536.	3.4	91
69	Kidney injury molecule-1 is a potential receptor for SARS-CoV-2. Journal of Molecular Cell Biology, 2021, 13, 185-196.	3.3	44
70	COVID-19 vaccines: where we stand and challenges ahead. Cell Death and Differentiation, 2021, 28, 626-639.	11.2	626
71	A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351. MAbs, 2021, 13, 1930636.	5.2	13
72	A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cellular and Molecular Immunology, 2021, 18, 318-327.	10.5	270
73	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multi-epitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Emerging Microbes and Infections, 2021, 10, 1931-1946.	6.5	11
74	Lentil lectin derived from <i>Lens culinaris</i> exhibit broad antiviral activities against SARS-CoV-2 variants. Emerging Microbes and Infections, 2021, 10, 1519-1529.	6.5	30
75	Bioinformatic and MD Analysis of N501Y SARS-CoV-2 (UK) Variant. IFIP Advances in Information and Communication Technology, 2021, , 1-13.	0.7	1

#	ARTICLE	IF	CITATIONS
76	20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment. Journal of Evidence-based Integrative Medicine, 2021, 26, 2515690X2110261.	2.6	16
77	Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. Computational and Structural Biotechnology Journal, 2021, 19, 3799-3809.	4.1	24
81	Evolution of antibody immunity to SARS-CoV-2. Nature, 2021, 591, 639-644.	27.8	1,355
82	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science, 2021, 28, 9.	7.0	167
84	Developing effective siRNAs to reduce the expression of key viral genes of COVID-19. International Journal of Biological Sciences, 2021, 17, 1521-1529.	6.4	17
85	Insights from genomes and genetic epidemiology of SARS-CoV-2 isolates from the state of Andhra Pradesh. Epidemiology and Infection, 2021, 149, .	2.1	2
89	Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2. Clinical and Translational Immunology, 2021, 10, e1260.	3.8	13
90	Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development. BioMed Research International, 2021, 2021, 1-11.	1.9	15
91	SARS-CoV-2 mutations: the biological trackway towards viral fitness. Epidemiology and Infection, 2021, 149, e110.	2.1	53
92	Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. Annual Review of Microbiology, 2021, 75, 19-47.	7.3	52
93	Transcriptomic Analysis of Respiratory Tissue and Cell Line Models to Examine Glycosylation Machinery during SARS-CoV-2 Infection. Viruses, 2021, 13, 82.	3.3	5
95	Identification of a novel lineage bat SARS-related coronaviruses that use bat ACE2 receptor. Emerging Microbes and Infections, 2021, 10, 1507-1514.	6.5	47
96	D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. Cell Reports, 2021, 34, 108630.	6.4	263
97	A Review on COVID-19 Diagnosis Tests Approved for Use in Brazil and the Impact on Pandemic Control. Brazilian Archives of Biology and Technology, 2021, 64, .	0.5	1
98	AutoVEM: An automated tool to real-time monitor epidemic trends and key mutations in SARS-CoV-2 evolution. Computational and Structural Biotechnology Journal, 2021, 19, 1976-1985.	4.1	9
99	Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. Viruses, 2021, 13, 134.	3.3	56
100	Structural Mapping of Mutations in Spike, RdRp and Orf3a Genes of SARS-CoV-2 in Influenza Like Illness (ILI) Patients. Viruses, 2021, 13, 136.	3.3	4
101	Statistical Challenges in the Analysis of Sequence and Structure Data for the COVID-19 Spike Protein. Journal of Data Science, 2021, , 314-333.	0.9	4

#	ARTICLE	IF	CITATIONS
103	The role of pseudotype neutralization assays in understanding SARS CoV-2. Oxford Open Immunology, 2021, 2, iqab005.	2.8	20
104	COVID-19 reinfection in the presence of neutralizing antibodies. National Science Review, 2021, 8, nwab006.	9.5	24
105	Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19. Heliyon, 2021, 7, e05951.	3.2	15
106	SARS-CoV-2 Genomic Variation in Space and Time in Hospitalized Patients in Philadelphia. MBio, 2021, 12, .	4.1	27
108	Comments on “Development of a PCR-RFLP method for detection of D614G mutation in SARS-CoV-2”. Infection, Genetics and Evolution, 2021, 87, 104661.	2.3	5
109	mRNA vaccines for COVID-19: what, why and how. International Journal of Biological Sciences, 2021, 17, 1446-1460.	6.4	185
110	A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nature Communications, 2021, 12, 288.	12.8	224
111	Triazavirin might be the new hope to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Ceska A Slovenska Farmacie, 2021, 70, 18-25.	0.2	9
116	Severe acute respiratory syndrome coronavirus 2 detected in placentas of 2 coronavirus disease 2019 “positive asymptomatic pregnant women” case report. AJOG Global Reports, 2021, 1, 100001.	1.0	3
118	Chemosensory Dysfunction in Patients with COVID-19: What Do We Learn from the Global Outbreak?. Current Allergy and Asthma Reports, 2021, 21, 6.	5.3	11
120	Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile. Science Advances, 2021, 7, .	10.3	29
121	An On-Line Cross-Sectional Questionnaire to Assess Knowledge of COVID-19 Pandemic among Citizens Tested for the SARS-CoV-2 Virus in Quito and Ibarra, Ecuador. International Journal of Environmental Research and Public Health, 2021, 18, 1691.	2.6	5
122	Phyldynamic analysis in the understanding of the current COVID-19 pandemic and its utility in vaccine and antiviral design and assessment. Human Vaccines and Immunotherapeutics, 2021, 17, 2437-2444.	3.3	7
123	Characterization of Critical Determinants of ACE2 “SARS CoV-2 RBD Interaction. International Journal of Molecular Sciences, 2021, 22, 2268.	4.1	24
124	COVID-19 outbreak in Malaysia: Decoding D614G mutation of SARS-CoV-2 virus isolated from an asymptomatic case in Pahang. Materials Today: Proceedings, 2022, 48, 828-836.	1.8	11
126	The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. ELife, 2021, 10, .	6.0	173
127	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. PLoS Pathogens, 2021, 17, e1009282.	4.7	42
129	The challenge of emerging SARS-CoV-2 mutants to vaccine development. Journal of Genetics and Genomics, 2021, 48, 102-106.	3.9	19

#	ARTICLE	IF	CITATIONS
130	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Reports, 2021, 34, 108699.	6.4	110
132	B cell memory: understanding COVID-19. Immunity, 2021, 54, 205-210.	14.3	102
133	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	27.8	1,232
135	Worldwide tracking of major SARS-CoV-2 genome haplotypes in sequences of June 1 to November 15, 2020 and discovery of rapid expansion of a new haplotype. Journal of Medical Virology, 2021, 93, 3251-3256.	5.0	4
137	Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Science Immunology, 2021, 6, .	11.9	153
138	SARS-CoV-2 spike D614G change enhances replication and transmission. Nature, 2021, 592, 122-127.	27.8	440
142	SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants. Journal of Biosciences, 2021, 46, 1.	1.1	79
144	Adaptive immunity to SARS-CoV-2 and COVID-19. Cell, 2021, 184, 861-880.	28.9	1,364
148	Comparative Study of Chemosensory Dysfunction in COVID-19 in 2 Geographically Distinct Regions. Ear, Nose and Throat Journal, 2021, , 014556132110001.	0.8	5
149	Insights into biological therapeutic strategies for COVID-19. Fundamental Research, 2021, 1, 166-178.	3.3	2
152	Does COVID-19 Vaccination Warrant the Classical Principle "eiusdem generis"? Medicina (Lithuania), 2021, 57, 253.	2.0	10
153	Mutations in SARS-CoV-2 nsp7 and nsp8 proteins and their predicted impact on replication/transcription complex structure. Journal of Medical Virology, 2021, 93, 4616-4619.	5.0	25
154	A multiplexed, next generation sequencing platform for high-throughput detection of SARS-CoV-2. Nature Communications, 2021, 12, 1405.	12.8	33
155	Development of a Colloidal Gold-Based Immunochromatographic Strip for Rapid Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein. Frontiers in Immunology, 2021, 12, 635677.	4.8	19
161	Multiplex bead binding assays using off-the-shelf components and common flow cytometers. Journal of Immunological Methods, 2021, 490, 112952.	1.4	10
165	Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host and Microbe, 2021, 29, 463-476.e6.	11.0	1,054
168	Variable routes to genomic and host adaptation among coronaviruses. Journal of Evolutionary Biology, 2021, 34, 924-936.	1.7	5
170	Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS ONE, 2021, 16, e0248348.	2.5	102

#	ARTICLE	IF	CITATIONS
171	Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. Transfusion, 2021, 61, 1705-1709.	1.6	41
172	A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism**. Angewandte Chemie, 2021, 133, 10367-10373.	2.0	16
173	Detection of the SARS-CoV-2 D614G mutation using engineered Cas12a guide RNA. Biotechnology Journal, 2021, 16, e2100040.	3.5	30
175	Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis. Biomolecules, 2021, 11, 390.	4.0	28
176	Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein. Heliyon, 2021, 7, e06564.	3.2	25
177	The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 632814.	4.8	62
178	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science, 2021, 372, 1413-1418.	12.6	468
179	Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus. Molecular Therapy - Methods and Clinical Development, 2021, 20, 350-356.	4.1	17
181	A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism**. Angewandte Chemie - International Edition, 2021, 60, 10279-10285.	13.8	106
182	Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19. Journal of Biomolecular Structure and Dynamics, 2021, , 1-17.	3.5	8
185	Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Reviews in Medical Virology, 2021, 31, e2231.	8.3	128
186	Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. Inflammopharmacology, 2021, 29, 343-366.	3.9	9
187	Impact of a New SARS-CoV-2 Variant on the Population: A Mathematical Modeling Approach. Mathematical and Computational Applications, 2021, 26, 25.	1.3	23
189	Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host and Microbe, 2021, 29, 477-488.e4.	11.0	700
190	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 2021, 184, 1171-1187.e20.	28.9	541
193	1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection. Frontiers in Pharmacology, 2021, 12, 634176.	3.5	28
194	Systematic profiling of SARS-CoV-2-specific IgG epitopes at amino acid resolution. Cellular and Molecular Immunology, 2021, 18, 1067-1069.	10.5	14
195	Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. Stem Cell Reports, 2021, 16, 398-411.	4.8	18

#	ARTICLE	IF	CITATIONS
196	Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines, 2021, 9, 243.	4.4	217
197	D614G substitution at the hinge region enhances the stability of trimeric SARS-CoV-2 spike protein. Bioinformatics, 2021, 17, 439-445.	0.5	7
201	Initial Insights Into the Genetic Epidemiology of SARS-CoV-2 Isolates From Kerala Suggest Local Spread From Limited Introductions. Frontiers in Genetics, 2021, 12, 630542.	2.3	11
202	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nature Communications, 2021, 12, 1403.	12.8	65
203	The effect of spike mutations on SARS-CoV-2 neutralization. Cell Reports, 2021, 34, 108890.	6.4	200
204	First Identified Cases of SARS-CoV-2 Variant P.1 in the United States – Minnesota, January 2021. Morbidity and Mortality Weekly Report, 2021, 70, 346-347.	15.1	23
205	Whole-genome sequencing of SARS-CoV-2 reveals the detection of G614 variant in Pakistan. PLoS ONE, 2021, 16, e0248371.	2.5	34
207	SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity. International Journal of Molecular Sciences, 2021, 22, 3060.	4.1	32
208	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Central Science, 2021, 7, 512-533.	11.3	217
210	Web resources facilitate drug discovery in treatment of COVID-19. Drug Discovery Today, 2021, 26, 2358-2366.	6.4	4
211	The 442th amino acid residue of the spike protein is critical for the adaptation to bat hosts for SARS-related coronaviruses. Virus Research, 2021, 295, 198307.	2.2	5
212	The Importance of Glycans of Viral and Host Proteins in Enveloped Virus Infection. Frontiers in Immunology, 2021, 12, 638573.	4.8	61
213	Prevalence of COVID-19 and Possible Antigenic Drifts in SARS-CoV-2 Spike Protein in Kurdistan Region-Iraq. Passer Journal, 2021, 3, 0-0.	0.2	0
215	Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. Cells, 2021, 10, 1052.	4.1	26
216	Biosensing Detection of the SARS-CoV-2 D614G Mutation. Trends in Genetics, 2021, 37, 299-302.	6.7	22
217	Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. PLoS ONE, 2021, 16, e0250780.	2.5	66
218	SARS-CoV-2 within-host diversity and transmission. Science, 2021, 372, .	12.6	278
219	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell, 2021, 184, 2362-2371.e9.	28.9	332

#	ARTICLE	IF	CITATIONS
220	Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA - Journal of the American Medical Association, 2021, 325, 1324.	7.4	306
222	The Yin and Yang of SARS-CoV-2 Mutation and Evolution. Mayo Clinic Proceedings, 2021, 96, 863-865.	3.0	4
223	Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase. Expert Opinion on Drug Discovery, 2021, 16, 1-15.	5.0	6
225	Practicability of serological assays for upscaling COVID-19 laboratory testing in Africa. Journal of Global Health, 2021, 11, 03038.	2.7	0
226	Bioinformatic prediction of immunodominant regions in spike protein for early diagnosis of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). PeerJ, 2021, 9, e11232.	2.0	5
228	Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies. Journal of Physical Chemistry B, 2021, 125, 4596-4619.	2.6	60
229	Geographical Variations in Host Predisposition to COVID-19 Related Anosmia, Ageusia, and Neurological Syndromes. Frontiers in Medicine, 2021, 8, 661359.	2.6	14
230	Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. Angewandte Chemie, 2021, 133, 13014-13020.	2.0	2
232	Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses. Cell Discovery, 2021, 7, 21.	6.7	20
236	Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective. Biomedicines, 2021, 9, 412.	3.2	22
237	Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes. Virology Journal, 2021, 18, 87.	3.4	27
238	Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern. Microorganisms, 2021, 9, 926.	3.6	48
239	D936Y and Other Mutations in the Fusion Core of the SARS-CoV-2 Spike Protein Heptad Repeat 1: Frequency, Geographical Distribution, and Structural Effect. Molecules, 2021, 26, 2622.	3.8	21
240	New framework for recombination and adaptive evolution analysis with application to the novel coronavirus SARS-CoV-2. Briefings in Bioinformatics, 2021, 22, .	6.5	7
241	Unraveling the stability landscape of mutations in the SARS-CoV-2 receptor-binding domain. Scientific Reports, 2021, 11, 9166.	3.3	13
242	Deciphering the introduction and transmission of SARS-CoV-2 in the Colombian Amazon Basin. PLoS Neglected Tropical Diseases, 2021, 15, e0009327.	3.0	6
245	Substantial impact of post-vaccination contacts on cumulative infections during viral epidemics. F1000Research, 2021, 10, 315.	1.6	7
249	Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19. Frontiers in Molecular Biosciences, 2021, 8, 635337.	3.5	22

#	ARTICLE	IF	CITATIONS
250	Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study. EBioMedicine, 2021, 66, 103319.	6.1	21
252	Antibodies and Vaccines Target RBD of SARS-CoV-2. Frontiers in Molecular Biosciences, 2021, 8, 671633.	3.5	108
253	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell, 2021, 184, 2332-2347.e16.	28.9	784
254	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host and Microbe, 2021, 29, 529-539.e3.	11.0	324
255	COVID-19 and the human innate immune system. Cell, 2021, 184, 1671-1692.	28.9	524
259	Can proteomics-based approaches further help COVID-19 prevention and therapy?. Expert Review of Proteomics, 2021, 18, 241-245.	3.0	5
260	Structural and Functional Characterization of SARS-CoV-2 RBD Domains Produced in Mammalian Cells. Analytical Chemistry, 2021, 93, 6839-6847.	6.5	39
261	CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases. Frontiers in Cellular and Infection Microbiology, 2021, 11, 639108.	3.9	13
262	SARS-CoV-2 variants combining spike mutations and the absence of ORF8 may be more transmissible and require close monitoring. Biochemical and Biophysical Research Communications, 2021, 550, 8-14.	2.1	31
263	Analysis of Key Factors of a SARS-CoV-2 Vaccination Program: A Mathematical Modeling Approach. Epidemiologia, 2021, 2, 140-161.	2.2	22
264	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microbial Cell Factories, 2021, 20, 88.	4.0	37
265	Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants. Journal of Virological Methods, 2021, 290, 114084.	2.1	1
267	Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science, 2021, 372, 525-530.	12.6	344
269	Short Communication:Evidence of Novel SARS-CoV-2 Variants Circulation in Romania. AIDS Research and Human Retroviruses, 2021, 37, 329-332.	1.1	8
270	SARS-CoV-2 one year on: evidence for ongoing viral adaptation. Journal of General Virology, 2021, 102, .	2.9	137
272	Killed whole-genome reduced-bacteria surface-expressed coronavirus fusion peptide vaccines protect against disease in a porcine model. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	24
274	Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. Angewandte Chemie - International Edition, 2021, 60, 12904-12910.	13.8	49
275	Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System. Journal of Personalized Medicine, 2021, 11, 475.	2.5	20

#	ARTICLE	IF	CITATIONS
276	Scrutinizing Coronaviruses Using Publicly Available Bioinformatic Tools: The Viral Structural Proteins as a Case Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671923.	3.5	0
277	In Vitro Diagnostics for COVID-19: State-of-the-Art, Future Directions and Role in Pandemic Response. , 0, , .		0
281	Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. <i>Journal of Virology</i> , 2021, 95, .	3.4	80
282	Catching a resurgence: Increase in SARS-CoV-2 viral RNA identified in wastewater 48Âh before COVID-19 clinical tests and 96Âh before hospitalizations. <i>Science of the Total Environment</i> , 2021, 770, 145319.	8.0	159
283	IgV somatic mutation of human antiâ€SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity. <i>JCI Insight</i> , 2021, 6, .	5.0	13
284	SARS-CoV-2 variants of concern are emerging in India. <i>Nature Medicine</i> , 2021, 27, 1131-1133.	30.7	310
285	High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. <i>Cell</i> , 2021, 184, 2927-2938.e11.	28.9	35
286	Developing a Paper-Based Antigen Assay to Differentiate between Coronaviruses and SARS-CoV-2 Spike Variants. <i>Analytical Chemistry</i> , 2021, 93, 7825-7832.	6.5	26
288	Antigenic Evolution on a Global Scale Reveals the Potential Natural Selection of Severe Acute Respiratory Syndrome-Coronavirus 2 by Pre-existing Cross-Reactive T-Cell Immunity. <i>Frontiers in Microbiology</i> , 2021, 12, 599562.	3.5	5
289	Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab268.	0.9	3
290	Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model. <i>Frontiers in Immunology</i> , 2021, 12, 641447.	4.8	20
293	Molecular Analysis of SARS-CoV-2 Circulating in Bangladesh during 2020 Revealed Lineage Diversity and Potential Mutations. <i>Microorganisms</i> , 2021, 9, 1035.	3.6	7
296	Cellular tropism and antigenicity of mink-derived SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 196.	17.1	7
297	Phytochemical Moieties From Indian Traditional Medicine for Targeting Dual Hotspots on SARS-CoV-2 Spike Protein: An Integrative in-silico Approach. <i>Frontiers in Medicine</i> , 2021, 8, 672629.	2.6	34
298	Graphene Oxide Nanosheets Interact and Interfere with SARSâ€CoVâ€2 Surface Proteins and Cell Receptors to Inhibit Infectivity. <i>Small</i> , 2021, 17, e2101483.	10.0	46
299	Immune profiling of COVID-19: preliminary findings and implications for the pandemic. , 2021, 9, e002550.		15
300	Induction of Humoral and Cellular Immunity by Intradermal Delivery of SARS-CoV-2 Nucleocapsid Protein Using Dissolvable Microneedles. <i>Journal of Immunology Research</i> , 2021, 2021, 1-8.	2.2	9
303	Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2. <i>Viruses</i> , 2021, 13, 927.	3.3	29

#	ARTICLE	IF	CITATIONS
304	Genomic epidemiology of SARS-CoV-2 in Esteio, Rio Grande do Sul, Brazil. BMC Genomics, 2021, 22, 371.	2.8	22
305	Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. International Reviews of Immunology, 2021, , 1-16.	3.3	6
306	Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates. Science Advances, 2021, 7, .	10.3	28
307	Evolution of SARS CoV-2 Coronavirus Surface Protein Investigated with Mass Spectrometry Based Phylogenetics. Analytical Letters, 0, , 1-13.	1.8	6
309	Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	69
310	Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. Frontiers in Immunology, 2021, 12, 688436.	4.8	26
313	Phylogenetic Analysis of the 2020 West Nile Virus (WNV) Outbreak in Andalusia (Spain). Viruses, 2021, 13, 836.	3.3	13
316	Comparison of Immunological Profiles of SARS-CoV-2 Variants in the COVID-19 Pandemic Trends: An Immunoinformatics Approach. Antibiotics, 2021, 10, 535.	3.7	11
317	Extensive genetic diversity with novel mutations in spike glycoprotein of severe acute respiratory syndrome coronavirus 2, Bangladesh in late 2020. New Microbes and New Infections, 2021, 41, 100889.	1.6	10
318	Targeted design of drug binding sites in the main protease of SARS-CoV-2 reveals potential signatures of adaptation. Biochemical and Biophysical Research Communications, 2021, 555, 147-153.	2.1	22
319	Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus. Microbial Pathogenesis, 2021, 154, 104831.	2.9	92
320	Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Nature Communications, 2021, 12, 3061.	12.8	149
321	Platforms for Personalized Polytherapeutics Discovery in COVID-19. Journal of Molecular Biology, 2021, 433, 166945.	4.2	4
327	Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka. Wellcome Open Research, 2021, 6, 110.	1.8	14
328	Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. Cell Reports, 2021, 35, 109109.	6.4	21
329	Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. Science Advances, 2021, 7, .	10.3	42
330	Clinical Efficacy of an Osmotic, Antiviral and Anti-Inflammatory Polymeric Nasal Film to Treat Covid-19 Early-Phase Respiratory Symptoms. Open Access Journal of Clinical Trials, 0, Volume 13, 11-20.	1.5	1
331	Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center. Clinical Infectious Diseases, 2022, 74, 821-828.	5.8	47

#	ARTICLE	IF	CITATIONS
332	Origin, evolution and global spread of SARS-CoV-2. <i>Comptes Rendus - Biologies</i> , 2021, 344, 57-75.	0.2	16
333	N-Glycosylation Network Construction and Analysis to Modify Glycans on the Spike (S) Glycoprotein of SARS-CoV-2. <i>Frontiers in Bioinformatics</i> , 2021, 1, .	2.1	5
335	Effect of Genomic and Amino Acid Sequence Mutation on Virulence and Therapeutic Target of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS COV-2). <i>Infection and Drug Resistance</i> , 2021, Volume 14, 2187-2192.	2.7	8
336	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. <i>Molecules and Cells</i> , 2021, 44, 392-400.	2.6	22
337	Relevant SARS-CoV-2 Genome Variation through Six Months of Worldwide Monitoring. <i>BioMed Research International</i> , 2021, 2021, 1-10.	1.9	6
338	Geographic Differences on Clinical Manifestations of COVID-19 Infection Between Overseas Chinese and Local Chinese Patients. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 2269-2277.	2.7	0
339	Molecular biology of the SARS-CoV-2 spike protein: A review of current knowledge. <i>Journal of Medical Virology</i> , 2021, 93, 5729-5741.	5.0	37
340	Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021. <i>MSystems</i> , 2021, 6, e0035321.	3.8	46
341	Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. <i>Nature Communications</i> , 2021, 12, 3815.	12.8	44
342	A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0074121.	3.9	38
343	Glyconanomaterials for Human Virus Detection and Inhibition. <i>Nanomaterials</i> , 2021, 11, 1684.	4.1	5
345	Molecular basis of cross-species ACE2 interactions with SARS-CoV-2-like viruses of pangolin origin. <i>EMBO Journal</i> , 2021, 40, e107786.	7.8	46
346	Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. <i>Nature Communications</i> , 2021, 12, 3661.	12.8	48
347	Ramping Up Antimicrobial Peptides Against Severe Acute Respiratory Syndrome Coronavirus-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 620806.	3.5	28
348	In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms. <i>Frontiers in Microbiology</i> , 2021, 12, 698944.	3.5	40
350	SARS-CoV-2 Infectivity and Severity of COVID-19 According to SARS-CoV-2 Variants: Current Evidence. <i>Journal of Clinical Medicine</i> , 2021, 10, 2635.	2.4	36
351	Predicting the development trend of the second wave of COVID-19 in five European countries. <i>Journal of Medical Virology</i> , 2021, 93, 5896-5907.	5.0	2
352	A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro. <i>Viruses</i> , 2021, 13, 1055.	3.3	4

#	ARTICLE	IF	CITATIONS
353	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 for viral entry. <i>Molecular Therapy</i> , 2021, 29, 1984-2000.	8.2	19
354	2D MXenes with antiviral and immunomodulatory properties: A pilot study against SARS-CoV-2. <i>Nano Today</i> , 2021, 38, 101136.	11.9	63
355	SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424.	28.6	2,650
356	Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda. <i>Nature Microbiology</i> , 2021, 6, 1094-1101.	13.3	82
357	This is not a pipe “ But how harmful is electronic cigarette smoke. <i>Biomedical Journal</i> , 2021, 44, 227-234.	3.1	0
358	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 676314.	3.5	17
359	V483A: an emerging mutation hotspot of SARS-CoV-2. <i>Future Virology</i> , 2021, 16, 419-429.	1.8	9
361	Notable and Emerging Variants of SARS-CoV-2 Virus: A Quick Glance. <i>Indian Journal of Clinical Biochemistry</i> , 2021, 36, 451-458.	1.9	9
362	N-Glycosylation of the SARS-CoV-2 Receptor Binding Domain Is Important for Functional Expression in Plants. <i>Frontiers in Plant Science</i> , 2021, 12, 689104.	3.6	34
364	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021, 54, 1276-1289.e6.	14.3	112
365	SARS-CoV-2 Variants in Lebanon: Evolution and Current Situation. <i>Biology</i> , 2021, 10, 531.	2.8	13
366	SARS-CoV-2 Genetic Variability and Non-Specific Immunity Associated with the Use of Different BCG Strains—A Molecular and Clinical Approach. <i>Vaccines</i> , 2021, 9, 639.	4.4	3
367	Comparative genomic analysis demonstrates that true reinfection following SARS-CoV-2 infection is possible. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100015.	1.0	0
368	Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes. <i>Vaccines</i> , 2021, 9, 702.	4.4	5
369	Is SARS-CoV-2 Spike glycoprotein impairing macrophage function via $\alpha 7$ -nicotinic acetylcholine receptors?. <i>Food and Chemical Toxicology</i> , 2021, 152, 112184.	3.6	10
370	A Novel SARS-CoV-2 Viral Sequence Bioinformatic Pipeline Has Found Genetic Evidence That the Viral 3' UTR Is Evolving and Generating Increased Viral Diversity. <i>Frontiers in Microbiology</i> , 2021, 12, 665041.	3.5	20
371	Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19. <i>Nature Nanotechnology</i> , 2021, 16, 942-951.	31.5	103
373	Rapid screening for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays targeting key mutations of the spike protein. <i>Water Research</i> , 2021, 197, 117104.	11.3	92

#	ARTICLE	IF	CITATIONS
374	SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. <i>Immunity</i> , 2021, 54, 1304-1319.e9.	14.3	115
375	Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 754-764.	4.1	5
376	Comparative analysis of mutational hotspots in the spike protein of SARS-CoV-2 isolates from different geographic origins. <i>Gene Reports</i> , 2021, 23, 101100.	0.8	3
378	The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. <i>Frontiers in Immunology</i> , 2021, 12, 687869.	4.8	23
379	Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species. <i>Cell</i> , 2021, 184, 3438-3451.e10.	28.9	100
380	Potential transmission chains of variant B.1.1.7 and co-mutations of SARS-CoV-2. <i>Cell Discovery</i> , 2021, 7, 44.	6.7	16
381	Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots. <i>Journal of Chemical Theory and Computation</i> , 2021, 17, 4578-4598.	5.3	39
382	An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. <i>Cell</i> , 2021, 184, 3452-3466.e18.	28.9	205
383	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108.	28.9	309
385	COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. <i>Molecular Biotechnology</i> , 2021, 63, 885-897.	2.4	8
386	Wearable materials with embedded synthetic biology sensors for biomolecule detection. <i>Nature Biotechnology</i> , 2021, 39, 1366-1374.	17.5	286
387	Machine Learning Reveals the Critical Interactions for SARS-CoV-2 Spike Protein Binding to ACE2. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 5494-5502.	4.6	44
388	Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 226.	17.1	103
391	Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies. <i>Frontiers in Microbiology</i> , 2021, 12, 698365.	3.5	16
392	Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. <i>Viruses</i> , 2021, 13, 1514.	3.3	12
393	Human immunoglobulin from transchromosomal bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	3.3	20
394	New SARS-CoV-2 Variant from Jordan. <i>Microbiology Resource Announcements</i> , 2021, 10, e0053221.	0.6	3
395	ACoRE: Accurate SARS-CoV-2 genome reconstruction for the characterization of intra-host and inter-host viral diversity in clinical samples and for the evaluation of re-infections. <i>Genomics</i> , 2021, 113, 1628-1638.	2.9	8

#	ARTICLE	IF	CITATIONS
396	Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach. <i>Infection, Genetics and Evolution</i> , 2021, 91, 104815.	2.3	8
397	Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7425.	4.1	69
398	SARS-CoV-2 receptor-binding mutations and antibody contact sites. <i>Antibody Therapeutics</i> , 2021, 4, 149-158.	1.9	12
399	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654.	12.6	385
400	A bivalent protein targeting glycans and HR1 domain in spike protein potentially inhibited infection of SARS-CoV-2 and other human coronaviruses. <i>Cell and Bioscience</i> , 2021, 11, 128.	4.8	9
401	Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern. <i>JCI Insight</i> , 2021, 6, .	5.0	32
402	Glycosylation of SARS-CoV-2: structural and functional insights. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 7179-7193.	3.7	56
403	Nonlinear Dynamics of the Introduction of a New SARS-CoV-2 Variant with Different Infectiousness. <i>Mathematics</i> , 2021, 9, 1564.	2.2	5
404	An Update on Severe Acute Respiratory Syndrome Coronavirus 2 Diversity in the US National Capital Region: Evolution of Novel and Variants of Concern. <i>Clinical Infectious Diseases</i> , 2022, 74, 1419-1428.	5.8	24
405	Non-permissive SARS-CoV-2 infection in human neurospheres. <i>Stem Cell Research</i> , 2021, 54, 102436.	0.7	19
406	N-terminal domain of SARS CoV-2 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals. <i>Journal of Medical Virology</i> , 2021, 93, 5726-5728.	5.0	19
408	V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. <i>Journal of Virology</i> , 2021, 95, e0061721.	3.4	90
409	SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. <i>PLoS Medicine</i> , 2021, 18, e1003656.	8.4	109
410	Qualitative analysis of a mathematical model with presymptomatic individuals and two SARS-CoV-2 variants. <i>Computational and Applied Mathematics</i> , 2021, 40, 1.	2.2	14
411	SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. <i>Cell Host and Microbe</i> , 2021, 29, 1124-1136.e11.	11.0	421
412	Comparison and Sensitivity Evaluation of Three Different Commercial Real-Time Quantitative PCR Kits for SARS-CoV-2 Detection. <i>Viruses</i> , 2021, 13, 1321.	3.3	31
413	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 36, 109415.	6.4	206
415	SARS-CoV-2 Mutations and their Viral Variants. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 10-22.	7.2	113

#	ARTICLE	IF	CITATIONS
416	SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors. Immunity, Inflammation and Disease, 2021, 9, 1452-1467.	2.7	12
417	L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus. JCI Insight, 2021, 6, .	5.0	31
418	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. Cell Host and Microbe, 2021, 29, 1093-1110.	11.0	73
419	Functionalized Masks: Powerful Materials against COVID-19 and Future Pandemics. Small, 2021, 17, e2102453.	10.0	82
420	A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19. Frontiers in Public Health, 2021, 9, 695139.	2.7	32
421	Immune Profile of SARS-CoV-2 Variants of Concern. Frontiers in Digital Health, 2021, 3, 704411.	2.8	3
424	Updated SARS-CoV-2 single nucleotide variants and mortality association. Journal of Medical Virology, 2021, 93, 6525-6534.	5.0	16
425	Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. Biochemical Pharmacology, 2021, 189, 114424.	4.4	27
428	Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant. Scientific Reports, 2021, 11, 13705.	3.3	45
429	Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein. ACS Pharmacology and Translational Science, 2021, 4, 1349-1361.	4.9	3
430	Comprehensive O-Glycosylation Analysis of the SARS-CoV-2 Spike Protein with Biomimetic Trp-Arg Materials. Analytical Chemistry, 2021, 93, 10444-10452.	6.5	13
431	Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. Molecular Biology, 2021, 55, 538-547.	1.3	2
432	Ongoing global and regional adaptive evolution of SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	196
433	SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms, 2021, 9, 1542.	3.6	521
434	The molecular basis for SARS-CoV-2 binding to dog ACE2. Nature Communications, 2021, 12, 4195.	12.8	43
435	A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants. Journal of Clinical Medicine, 2021, 10, 3276.	2.4	18
436	Time scale performance of rapid antigen testing for SARS-CoV-2: Evaluation of 10 rapid antigen assays. Journal of Medical Virology, 2021, 93, 6512-6518.	5.0	16
437	Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants. Virologica Sinica, 2021, 36, 934-947.	3.0	12

#	ARTICLE	IF	CITATIONS
438	Detection of SARS-CoV-2 in Wastewater: Community Variability, Temporal Dynamics, and Genotype Diversity. ACS ES&T Water, 2021, 1, 1816-1825.	4.6	7
439	Tracking the pipeline: immunoinformatics and the COVID-19 vaccine design. Briefings in Bioinformatics, 2021, 22, .	6.5	12
440	SARS-CoV-2 reinfection with a virus harboring mutation in the Spike and the Nucleocapsid proteins in Panama. International Journal of Infectious Diseases, 2021, 108, 588-591.	3.3	15
441	Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants. Cell Discovery, 2021, 7, 53.	6.7	14
443	Free Energy Landscapes from SARS-CoV-2 Spike Glycoprotein Simulations Suggest that RBD Opening Can Be Modulated via Interactions in an Allosteric Pocket. Journal of the American Chemical Society, 2021, 143, 11349-11360.	13.7	54
444	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. Biochemical Journal, 2021, 478, 2405-2423.	3.7	46
445	Rise and Fall of SARS-CoV-2 Lineage A.27 in Germany. Viruses, 2021, 13, 1491.	3.3	9
446	Computational assessment of select antiviral phytochemicals as potential SARS-Cov-2 main protease inhibitors: molecular dynamics guided ensemble docking and extended molecular dynamics. In Silico Pharmacology, 2021, 9, 44.	3.3	15
448	Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased Transmissibility. Journal of Molecular Biology, 2021, 433, 167051.	4.2	67
449	Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19). Frontiers in Medicine, 2021, 8, 702066.	2.6	14
450	A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Science Translational Medicine, 2021, 13, .	12.4	68
452	Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2. PLoS ONE, 2021, 16, e0254734.	2.5	12
454	Design and proof of concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	35
456	The Rise and Fall of a Local SARS-CoV-2 Variant with the Spike Protein Mutation L452R. Vaccines, 2021, 9, 937.	4.4	12
459	Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting Peptide. Frontiers in Medicine, 2021, 8, 675963.	2.6	6
461	Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2. Frontiers in Immunology, 2021, 12, 715464.	4.8	11
462	A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. Nature Communications, 2021, 12, 5000.	12.8	37
464	Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. , 2022, 230, 107967.		40

#	ARTICLE	IF	CITATIONS
465	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine, 2021, 385, 585-594.	27.0	2,411
467	An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection. Cell and Bioscience, 2021, 11, 164.	4.8	10
468	Direct detection of SARS-CoV-2 antisense and sense genomic RNA in human saliva by semi-autonomous fluorescence in situ hybridization: A proxy for contagiousness?. PLoS ONE, 2021, 16, e0256378.	2.5	7
469	Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. Cell Discovery, 2021, 7, 67.	6.7	29
470	Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants. Journal of Clinical Microbiology, 2021, 59, e0092121.	3.9	140
471	Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS-CoV-2 lineage in Peru despite circulation of variants of concern. Journal of Medical Virology, 2021, 93, 6845-6849.	5.0	47
472	Substantial impact of post-vaccination contacts on cumulative infections during viral epidemics. F1000Research, 2021, 10, 315.	1.6	9
474	Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. Vaccine: X, 2021, 8, 100098.	2.1	9
476	Molecular Level Dissection of Critical Spike Mutations in SARS-CoV-2 Variants of Concern (VOCs): A Simplified Review. ChemistrySelect, 2021, 6, 7981-7998.	1.5	18
477	Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. Vaccines, 2021, 9, 869.	4.4	17
478	Probing the Allosteric Inhibition Mechanism of a Spike Protein Using Molecular Dynamics Simulations and Active Compound Identifications. Journal of Medicinal Chemistry, 2022, 65, 2827-2835.	6.4	15
479	Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian) Tj ETQq1 1 0.784314 rgBT /Overl	0.5	3
480	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight, 2021, 6, .	5.0	33
482	ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker. Signal Transduction and Targeted Therapy, 2021, 6, 315.	17.1	53
483	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. Infection, Genetics and Evolution, 2021, 92, 104869.	2.3	49
484	Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic. Environmental Microbiology, 2022, 24, 2615-2629.	3.8	23
486	Artemether, Artesunate, Arteannuin B, Echinatin, Licochalcone B and Andrographolide Effectively Inhibit SARS-CoV-2 and Related Viruses In Vitro. Frontiers in Cellular and Infection Microbiology, 2021, 11, 680127.	3.9	28
487	One-shot identification of SARS-CoV-2 RBD escape mutants using yeast screening. Cell Reports, 2021, 36, 109627.	6.4	35

#	ARTICLE	IF	CITATIONS
488	SARS-CoV-2 Genomic Sequencing Revealed N501Y and L452R Mutants of S/A Lineage in Tianjin Municipality, China. <i>Virologica Sinica</i> , 2021, 36, 1228-1231.	3.0	2
490	N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 697035.	3.7	19
491	Evolutionary trajectory of SARS-CoV-2 and emerging variants. <i>Virology Journal</i> , 2021, 18, 166.	3.4	105
493	Evolutionary Tracking of SARS-CoV-2 Genetic Variants Highlights an Intricate Balance of Stabilizing and Destabilizing Mutations. <i>MBio</i> , 2021, 12, e0118821.	4.1	30
494	Modelling conformational state dynamics and its role on infection for SARS-CoV-2 Spike protein variants. <i>PLoS Computational Biology</i> , 2021, 17, e1009286.	3.2	79
495	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. <i>Immunity</i> , 2021, 54, 2385-2398.e10.	14.3	46
497	SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. <i>Viruses</i> , 2021, 13, 1687.	3.3	57
498	Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. <i>Science Immunology</i> , 2021, 6, .	11.9	20
499	Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals. <i>MSphere</i> , 2021, 6, e0057121.	2.9	2
500	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	14.5	57
501	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1652-1661.	12.0	24
502	Molecular characterization of SARS-CoV-2 from Bangladesh: implications in genetic diversity, possible origin of the virus, and functional significance of the mutations. <i>Heliyon</i> , 2021, 7, e07866.	3.2	14
503	Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8498.	4.1	11
504	The Promise of Mutation Resistant Drugs for SARS-CoV-2 That Interdict in the Folding of the Spike Protein Receptor Binding Domain. <i>Covid</i> , 2021, 1, 288-302.	1.5	3
505	Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2489-2509.	4.0	52
506	MALDI-ToF protein profiling as a potential rapid diagnostic platform for COVID-19. <i>Journal of Mass Spectrometry and Advances in the Clinical Lab</i> , 2021, 21, 31-41.	2.4	20
507	Systematic review of host genetic association with Covidâ€™19 prognosis and susceptibility: What have we learned in 2020?. <i>Reviews in Medical Virology</i> , 2022, 32, e2283.	8.3	15
508	Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice. <i>Viruses</i> , 2021, 13, 1595.	3.3	23

#	ARTICLE	IF	CITATIONS
509	Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein. Journal of Biomolecular Structure and Dynamics, 2022, 40, 12209-12220.	3.5	10
510	Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. PLoS Pathogens, 2021, 17, e1009772.	4.7	74
511	IMPACT OF VACCINATION ON COVID INFECTION IN HEALTH CARE WORKERS IN WESTERN ZONE OF INDIAN RAILWAYS. , 2021, , 31-34.		0
512	Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites. EMBO Journal, 2021, 40, e108375.	7.8	44
513	Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clinical Microbiology and Infection, 2021, 27, 1109-1117.	6.0	290
514	Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants. Cell Research, 2021, 31, 1130-1133.	12.0	34
516	SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response. MBio, 2021, 12, e0233521.	4.1	57
517	SAS: A Platform of Spike Antigenicity for SARS-CoV-2. Frontiers in Cell and Developmental Biology, 2021, 9, 713188.	3.7	1
518	Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines. Vaccines, 2021, 9, 992.	4.4	53
520	S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis. Signal Transduction and Targeted Therapy, 2021, 6, 343.	17.1	24
521	Repurposing fusion inhibitor peptide against SARS-CoV-2. Journal of Computational Chemistry, 2021, 42, 2283-2293.	3.3	14
523	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Reports, 2021, 36, 109760.	6.4	80
525	Whole-Genome Sequencing of SARS-CoV-2: Assessment of the Ion Torrent AmpliSeq Panel and Comparison with the Illumina MiSeq ARTIC Protocol. Journal of Clinical Microbiology, 2021, 59, e0064921.	3.9	24
526	Molecular evolutionary characteristics of SARS-CoV-2 emerging in the United States. Journal of Medical Virology, 2022, 94, 310-317.	5.0	59
527	Genome Sequences of the Delta Variant (B.1.617.2) and the Kappa Variant (B.1.617.1) Detected in Morocco. Microbiology Resource Announcements, 2021, 10, e0072721.	0.6	6
528	Protons to Patients: targeting endosomal Na ⁺ /H ⁺ exchangers against COVID-19 and other viral diseases. FEBS Journal, 2021, 288, 5071-5088.	4.7	6
530	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nature Microbiology, 2021, 6, 1233-1244.	13.3	237
531	The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants. Current Medicinal Chemistry, 2022, 29, 2673-2690.	2.4	12

#	ARTICLE	IF	CITATIONS
532	Interactions of the Receptor Binding Domain of SARS-CoV-2 Variants with hACE2: Insights from Molecular Docking Analysis and Molecular Dynamic Simulation. <i>Biology</i> , 2021, 10, 880.	2.8	38
533	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	16.3	778
534	Magnesium treatment on methylation changes of transmembrane serine protease 2 (TMPRSS2). <i>Nutrition</i> , 2021, 89, 111340.	2.4	6
535	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	3.2	87
536	Insilico study on the effect of SARS-CoV-2 RBD hotspot mutantsâ€™ interaction with ACE2 to understand the binding affinity and stability. <i>Virology</i> , 2021, 561, 107-116.	2.4	44
538	Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients. <i>Viruses</i> , 2021, 13, 1743.	3.3	15
539	A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels. <i>Scientific Reports</i> , 2021, 11, 18428.	3.3	10
540	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	16
541	Differential mutation profile of SARS-CoV-2 proteins across deceased and asymptomatic patients. <i>Chemico-Biological Interactions</i> , 2021, 347, 109598.	4.0	13
542	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. <i>Cell Host and Microbe</i> , 2021, 29, 1437-1453.e8.	11.0	53
543	Multiplex Biosensing for Simultaneous Detection of Mutations in SARS-CoV-2. <i>ACS Omega</i> , 2021, 6, 25846-25859.	3.5	21
544	Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1936.	3.3	9
545	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	28.9	131
546	Automatic label-free immunoassay with high sensitivity for rapid detection of SARS-CoV-2 nucleocapsid protein based on chemiluminescent magnetic beads. <i>Sensors and Actuators B: Chemical</i> , 2021, 349, 130739.	7.8	24
547	Case report: change of dominant strain during dual SARS-CoV-2 infection. <i>BMC Infectious Diseases</i> , 2021, 21, 959.	2.9	32
548	Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies. <i>Journal of Chemical Theory and Computation</i> , 2021, 17, 6559-6569.	5.3	13
549	Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	61
550	Wave-wise comparative genomic study for revealing the complete scenario and dynamic nature of COVID-19 pandemic in Bangladesh. <i>PLoS ONE</i> , 2021, 16, e0258019.	2.5	13

#	ARTICLE	IF	CITATIONS
551	COVID-19's U.S. Temperature Response Profile. <i>Environmental and Resource Economics</i> , 2021, 80, 675-704.	3.2	3
552	Pseudoephedrine and its derivatives antagonize wild and mutated severe acute respiratory syndrome <scp>â€CoV</scp>â€2 viruses through blocking virus invasion and antiinflammatory effect. <i>Phytotherapy Research</i> , 2021, 35, 5847-5860.	5.8	8
554	Mutation hotspots and spatiotemporal distribution of SARS-CoV-2 lineages in Brazil, February 2020-2021. <i>Virus Research</i> , 2021, 304, 198532.	2.2	15
555	Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19. <i>Vaccine</i> , 2021, 39, 6050-6056.	3.8	5
556	Discovery and evolution of 12N-substituted alopentine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage. <i>Bioorganic Chemistry</i> , 2021, 115, 105196.	4.1	5
557	The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. <i>Journal of Infection</i> , 2021, 83, e1-e3.	3.3	146
558	dsmCRISPR: Dual synthetic mismatches CRISPR/Cas12a-based detection of SARS-CoV-2 D614G mutation. <i>Virus Research</i> , 2021, 304, 198530.	2.2	23
559	In silico study of some selective phytochemicals against a hypothetical SARS-CoV-2 spike RBD using molecular docking tools. <i>Computers in Biology and Medicine</i> , 2021, 137, 104818.	7.0	23
560	COVID-19, the first pandemic in the post-genomic era. <i>Current Opinion in Virology</i> , 2021, 50, 40-48.	5.4	40
561	The Emergence of the New P.4 Lineage of SARS-CoV-2 With Spike L452R Mutation in Brazil. <i>Frontiers in Public Health</i> , 2021, 9, 745310.	2.7	8
562	COVID flood, can vaccines withstand?. <i>Medicine Updates</i> , 2021, 7, 51-62.	0.0	1
563	GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112011.	5.6	6
564	SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2021, 579, 69-75.	2.1	15
565	Evolutionary analysis and lineage designation of SARS-CoV-2 genomes. <i>Science Bulletin</i> , 2021, 66, 2297-2311.	9.0	26
566	SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166264.	3.8	5
567	Rapid, inexpensive methods for exploring SARS CoV-2 D614G mutation. <i>Meta Gene</i> , 2021, 30, 100950.	0.6	3
568	Highly sensitive and ultra-rapid antigen-based detection of SARS-CoV-2 using nanomechanical sensor platform. <i>Biosensors and Bioelectronics</i> , 2022, 195, 113647.	10.1	34
570	Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System. <i>Nephron</i> , 2021, 145, 392-403.	1.8	58

#	ARTICLE	IF	CITATIONS
572	Dynamic Network Modeling of Allosteric Interactions and Communication Pathways in the SARS-CoV-2 Spike Trimer Mutants: Differential Modulation of Conformational Landscapes and Signal Transmission via Cascades of Regulatory Switches. <i>Journal of Physical Chemistry B</i> , 2021, 125, 850-873.	2.6	66
575	Human <scp>SARS CoV</scp>â€™ spike protein mutations. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 569-576.	2.6	150
578	Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2. <i>Zoological Research</i> , 2021, 42, 170-181.	2.1	3
579	Treatment Approach, Pharmacological Agents and Vaccines. , 2021, , 145-162.		0
582	COVID-19 vaccines: Where do we stand?. <i>The EuroBiotech Journal</i> , 2021, 5, 4-7.	1.0	1
583	Intra-host evolution during SARS-CoV-2 prolonged infection. <i>Virus Evolution</i> , 2021, 7, veab078.	4.9	68
584	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. <i>Emerging Microbes and Infections</i> , 2021, 10, 507-535.	6.5	202
586	The emerging SARS-CoV-2 variants of concern. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110243.	1.8	82
587	Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective. <i>Antibody Therapeutics</i> , 2020, 3, 285-299.	1.9	34
588	The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. <i>Briefings in Bioinformatics</i> , 2021, 22, 742-768.	6.5	29
589	The development of neutralizing antibodies against SARS-CoV-2 and their common features. <i>Journal of Molecular Cell Biology</i> , 2021, 12, 980-986.	3.3	13
637	Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants. <i>Journal of Translational Medicine</i> , 2020, 18, 494.	4.4	15
638	Molecular-Level Anatomy of SARS-CoV-2 for the Battle against the COVID-19 Pandemic. <i>Bulletin of the Chemical Society of Japan</i> , 2021, 94, 1478-1490.	3.2	24
639	Antibody response to SARS-CoV-2 infection in humans: A systematic review. <i>PLoS ONE</i> , 2020, 15, e0244126.	2.5	269
640	Humanized COVIDâ€™19 decoy antibody effectively blocks viral entry and prevents SARSâ€™CoVâ€™2 infection. <i>EMBO Molecular Medicine</i> , 2021, 13, e12828.	6.9	43
641	Blocking Effect of Demethylzeylasteral on the Interaction between Human ACE2 Protein and SARS-CoV-2 RBD Protein Discovered Using SPR Technology. <i>Molecules</i> , 2021, 26, 57.	3.8	27
642	Global Prevalence of Adaptive and Prolonged Infectionsâ€™™ Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2021, 13, 1974.	3.3	9
643	Structureâ€™Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5133-5140.	5.4	21

#	ARTICLE	IF	CITATIONS
644	Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. <i>Genome Medicine</i> , 2021, 13, 164.	8.2	42
645	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2022, 160, 261-272.	2.8	7
646	The Rapid Assessment of Aggregated Wastewater Samples for Genomic Surveillance of SARS-CoV-2 on a City-Wide Scale. <i>Pathogens</i> , 2021, 10, 1271.	2.8	15
649	Genomic surveillance of SARS-CoV-2 tracks early interstate transmission of P.1 lineage and diversification within P.2 clade in Brazil. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009835.	3.0	23
650	Role of multiple factors likely contributing to severity-mortality of COVID-19. <i>Infection, Genetics and Evolution</i> , 2021, 96, 105101.	2.3	7
652	Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. <i>Scientific Reports</i> , 2021, 11, 20274.	3.3	33
653	InÂvivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential. <i>Cell Reports</i> , 2021, 37, 109838.	6.4	8
655	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	37.0	1,532
656	The global epidemic of SARSâ€CoVâ€2 variants and their mutational immune escape. <i>Journal of Medical Virology</i> , 2022, 94, 847-857.	5.0	80
657	Development of surfaceâ€enhanced Raman scattering<sc>â€based</sc> immunoassay platforms using hollow Au nanostars for reliable <sc>SARSâ€CoV</sc>â€2 diagnosis. <i>Bulletin of the Korean Chemical Society</i> , 2021, 42, 1699-1705.	1.9	15
658	Uncovering a conserved vulnerability site in SARSâ€CoVâ€2 by a human antibody. <i>EMBO Molecular Medicine</i> , 2021, 13, e14544.	6.9	17
659	Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. <i>Journal of Virology</i> , 2022, 96, JVI0111021.	3.4	29
660	Endonuclease-based genotyping of the RBM as a method to track the emergence or evolution of SARS-CoV-2 variants. <i>IScience</i> , 2021, 24, 103329.	4.1	0
661	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccineâ€boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	12.6	83
662	Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 720357.	3.9	7
663	Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. <i>Microbiology Spectrum</i> , 2021, 9, e0135221.	3.0	13
665	SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China. <i>Frontiers in Public Health</i> , 2021, 9, 716483.	2.7	2
666	Conformational variability of loops in the <sc>SARSâ€CoV</sc>â€2 spike protein. <i>Proteins: Structure, Function and Bioinformatics</i> , 2022, 90, 691-703.	2.6	1

#	ARTICLE	IF	CITATIONS
667	Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization. <i>Communications Biology</i> , 2021, 4, 1196.	4.4	49
668	Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 6103.	12.8	117
669	Mechanisms of Lung Injury Induced by SARS-CoV-2 Infection. <i>Physiology</i> , 2022, 37, 88-100.	3.1	18
672	Temporal-Geographical Dispersion of SARS-CoV-2 Spike Glycoprotein Variant Lineages and Their Functional Prediction Using in Silico Approach. <i>MBio</i> , 2021, 12, e0268721.	4.1	3
673	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. <i>Science Advances</i> , 2021, 7, eabj3107.	10.3	23
674	SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 368.	17.1	38
675	Nanodiagnostics to Face SARS-CoV-2 and Future Pandemics: From an Idea to the Market and Beyond. <i>ACS Nano</i> , 2021, 15, 17137-17149.	14.6	32
676	High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 2177.	3.3	21
677	Gold-Nanostar-Chitosan-Mediated Delivery of SARS-CoV-2 DNA Vaccine for Respiratory Mucosal Immunization: Development and Proof-of-Principle. <i>ACS Nano</i> , 2021, 15, 17582-17601.	14.6	55
678	Immunology and controlling of coronaviruses; the current enemy for humanity: A review. <i>International Journal of Biological Macromolecules</i> , 2021, , .	7.5	3
679	Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. <i>IScience</i> , 2021, 24, 103393.	4.1	17
682	Narrative review of the novel coronavirus SARS-CoV-2: update on genomic characteristics, transmissions and animal model. <i>Journal of Thoracic Disease</i> , 2020, 12, 7454-7466.	1.4	1
683	SARS-CoV-2 mutation hotspots incidence in different geographic regions. <i>Microbial Biosystems Journal</i> , 2020, 5, 1-8.	0.6	3
686	Association of SARS-CoV-2 Clades with Clinical, Inflammatory and Virologic Outcomes: An Observational Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
687	Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections. <i>Frontiers in Immunology</i> , 2021, 12, 742167.	4.8	32
688	Analysis of SARS-COV2 spike protein variants among Iraqi isolates. <i>Gene Reports</i> , 2022, 26, 101420.	0.8	12
689	Self and Nonself Short Constituent Sequences of Amino Acids in the SARS-CoV-2 Proteome for Vaccine Development. <i>Covid</i> , 2021, 1, 555-574.	1.5	4
690	First whole genome analysis of the novel coronavirus (SARS-CoV-2) obtained from COVID-19 patients from five districts in Western Serbia. <i>Epidemiology and Infection</i> , 0, , 1-31.	2.1	5

#	ARTICLE	IF	CITATIONS
691	Platelet extracellular vesicles in COVID-19: Potential markers and makers. <i>Journal of Leukocyte Biology</i> , 2021, 111, 63-74.	3.3	26
692	Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7967-7989.	5.4	40
693	Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 31-56.	1.4	8
694	Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs. <i>Frontiers in Microbiology</i> , 2021, 12, 758948.	3.5	11
695	Transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2), delta variant, between two fully vaccinated healthcare personnel. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1983-1985.	1.8	1
696	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	4.8	44
697	Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies. <i>Antiviral Research</i> , 2021, 196, 105206.	4.1	1
698	Genomic surveillance reveals the detection of SARS-CoV-2 delta, beta, and gamma VOCs during the third wave in Pakistan. <i>Journal of Medical Virology</i> , 2022, 94, 1115-1129.	5.0	21
699	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 378.	17.1	26
706	Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawai'i Reveals the Worldwide Emerging P681H Mutation. <i>Hawai'i Journal of Health & Social Welfare</i> , 2021, 80, 52-61.	0.2	25
707	Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment. <i>American Journal of Cancer Research</i> , 2021, 11, 827-836.	1.4	1
708	Delta variant of COVID-19: A simple explanation. <i>Qatar Medical Journal</i> , 2021, 2021, 49.	0.5	6
709	D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 9035-9045.	3.6	34
710	Exposing structural variations in SARS-CoV-2 evolution. <i>Scientific Reports</i> , 2021, 11, 22042.	3.3	6
711	Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 18-29.	6.5	25
712	Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein. <i>Journal of Virology</i> , 2022, 96, JVI0162621.	3.4	24
713	COVID-19 vaccinations: The unknowns, challenges, and hopes. <i>Journal of Medical Virology</i> , 2022, 94, 1336-1349.	5.0	75
714	A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions. <i>MBio</i> , 2021, , e0293621.	4.1	1

#	ARTICLE	IF	CITATIONS
715	PD-1 blockade counteracts postâ€“COVID-19 immune abnormalities and stimulates the antiâ€“SARS-CoV-2 immune response. JCI Insight, 2021, 6, .	5.0	51
716	Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	2.0	1
717	Underlying selection for the diversity of spike protein sequences of <scp>SARSâ€“CoV</scp>â€“2. IUBMB Life, 2022, 74, 213-220.	3.4	4
718	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. Archives of Virology, 2022, 167, 293-305.	2.1	28
719	The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape. Frontiers in Immunology, 2021, 12, 751778.	4.8	142
720	Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. Viruses, 2021, 13, 2295.	3.3	13
721	Neurological consequences of COVID-19 and brain related pathogenic mechanisms: A new challenge for neuroscience. Brain, Behavior, & Immunity - Health, 2022, 19, 100399.	2.5	33
722	Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19. Journal of Nanobiotechnology, 2021, 19, 391.	9.1	17
723	Targeted Detection of SARS-CoV-2 Nucleocapsid Sequence Variants by Mass Spectrometric Analysis of Tryptic Peptides. Journal of Proteome Research, 2022, 21, 142-150.	3.7	9
724	The glycosylation in SARS-CoV-2 and its receptor ACE2. Signal Transduction and Targeted Therapy, 2021, 6, 396.	17.1	111
725	Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. Journal of Infectious Diseases, 2022, 225, 777-784.	4.0	21
726	Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. Clinical Microbiology Reviews, 2022, 35, e0012321.	13.6	10
728	Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance. Current Opinion in Pharmacology, 2022, 62, 64-73.	3.5	29
729	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Seminars in Immunology, 2021, 55, 101533.	5.6	72
730	Phylogenomics and population genomics of SARS-CoV-2 in Mexico during the pre-vaccination stage reveals variants of interest B.1.1.28.4 and B.1.1.222 or B.1.1.519 and the nucleocapsid mutation S194L associated with symptoms. Microbial Genomics, 2021, 7, .	2.0	13
731	Implications of testicular ACE2 and the reninâ€“angiotensin system for SARS-CoV-2 on testis function. Nature Reviews Urology, 2022, 19, 116-127.	3.8	29
732	Emerging SARSâ€“CoVâ€“2 variants can potentially break set epidemiological barriers in COVIDâ€“19. Journal of Medical Virology, 2022, 94, 1300-1314.	5.0	32
733	CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern. Microbiology Spectrum, 2021, 9, e0101721.	3.0	40

#	ARTICLE	IF	CITATIONS
734	A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain). <i>Emerging Microbes and Infections</i> , 2022, 11, 172-181.	6.5	17
735	Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations. <i>Frontiers in Immunology</i> , 2021, 12, 730099.	4.8	15
736	Phyldynamic analysis and spike protein mutations in porcine deltacoronavirus with a new variant introduction in Taiwan. <i>Virus Evolution</i> , 2021, 7, veab096.	4.9	2
737	Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021. <i>Infection, Genetics and Evolution</i> , 2022, 97, 105164.	2.3	9
739	Codon usage, phylogeny and binding energy estimation predict the evolution of SARS-CoV-2. <i>One Health</i> , 2021, 13, 100352.	3.4	2
740	Delta variant of COVID-19: A simple explanation. <i>Qatar Medical Journal</i> , 2021, 2021, 49.	0.5	11
741	A second functional furin site in the SARS-CoV-2 spike protein. <i>Emerging Microbes and Infections</i> , 2022, 11, 182-194.	6.5	19
742	Toward a next-generation diagnostic tool: A review on emerging isothermal nucleic acid amplification techniques for the detection of SARS-CoV-2 and other infectious viruses. <i>Analytica Chimica Acta</i> , 2022, 1209, 339338.	5.4	24
743	Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5145-5147.	3.3	0
744	Rapid Identification of SARS-CoV-2 Variants of Concern Using a Portable <i>peak</i> PCR Platform. <i>Analytical Chemistry</i> , 2021, 93, 16350-16359.	6.5	17
745	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. <i>ACS Infectious Diseases</i> , 2022, 8, 29-58.	3.8	32
746	Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. <i>PLoS Pathogens</i> , 2021, 17, e1010022.	4.7	139
748	Evolutionary Dynamics of Indels in SARS-CoV-2 Spike Glycoprotein. <i>Evolutionary Bioinformatics</i> , 2021, 17, 117693432110646.	1.2	5
749	Detection of SARS-CoV-2 through pool testing for COVID-19: an integrative review. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2021, 54, e0276.	0.9	4
750	Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection (Russian translation). <i>Juvenis Scientia</i> , 2021, 7, 28-59.	0.2	1
751	Rapid and Parallel Adaptive Mutations in Spike S1 Drive Clade Success in SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
752	Phyldynamic pattern of genetic clusters, paradigm shift on spatio-temporal distribution of clades, and impact of spike glycoprotein mutations of SARS-CoV-2 isolates from India. <i>Journal of Global Infectious Diseases</i> , 2021, 13, 164.	0.5	3
753	SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD. <i>Immune Network</i> , 2021, 21, e39.	3.6	3

#	ARTICLE	IF	CITATIONS
754	In Silico Screening of Potential Phytocompounds from Several Herbs against SARS-CoV-2 Indian Delta Variant B.1.617.2 to Inhibit the Spike Glycoprotein Trimer. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 665.	2.5	8
755	Two-step fitness selection for intra-host variations in SARS-CoV-2. <i>Cell Reports</i> , 2022, 38, 110205.	6.4	38
756	ACE2-IgG1 fusions with improved inÂvitro and inÂvivo activity against SARS-CoV-2. <i>IScience</i> , 2022, 25, 103670.	4.1	29
757	A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. <i>Gene</i> , 2022, 813, 146113.	2.2	8
758	From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. <i>Gene</i> , 2022, 814, 146134.	2.2	97
759	Functional nucleic acids as modular components against SARS-CoV-2: From diagnosis to therapeutics. <i>Biosensors and Bioelectronics</i> , 2022, 201, 113944.	10.1	17
761	N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry. <i>Scientific Reports</i> , 2021, 11, 23561.	3.3	14
762	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. <i>Cell Research</i> , 2022, 32, 269-287.	12.0	54
763	Review on Drug Regulatory Science Promoting COVID-19 Vaccine Development in China. <i>Engineering</i> , 2022, 10, 127-132.	6.7	6
765	A short plus long-amplicon based sequencing approach improves genomic coverage and variant detection in the SARS-CoV-2 genome. <i>PLoS ONE</i> , 2022, 17, e0261014.	2.5	11
766	SARS-CoV-2 Virology. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 251-265.	5.1	7
770	The "LLQY" motif on SARS-CoV-2 spike protein affects S incorporation into virus particles. <i>Journal of Virology</i> , 2022, ,jvi0189721.	3.4	1
771	The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance. <i>Cell Reports</i> , 2022, 38, 110218.	6.4	148
772	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	16.0	9
773	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	4.8	176
774	An encodable multiplex microsphere-phase amplification sensing platform detects SARS-CoV-2 mutations. <i>Biosensors and Bioelectronics</i> , 2022, 203, 114032.	10.1	7
775	Monoclonal Antibodies and their Target Specificity Against SARS-CoV-2 Infections: Perspectives and Challenges. <i>Recent Patents on Biotechnology</i> , 2022, 16, 64-78.	0.8	3
776	Critical Mutations of the SARS-CoV-2 Virus. <i>WSEAS Transactions on Biology and Biomedicine</i> , 2022, 19, 22-30.	0.5	1

#	ARTICLE	IF	CITATIONS
778	Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein. <i>Structure</i> , 2022, 30, 590-607.e4.	3.3	24
779	A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States. <i>Viruses</i> , 2022, 14, 104.	3.3	1
781	Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India. <i>Journal of Infection and Public Health</i> , 2022, 15, 42-50.	4.1	3
783	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	2.6	22
784	SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection. <i>PLoS Pathogens</i> , 2022, 18, e1010242.	4.7	7
785	Digital Microfluidic qPCR Cartridge for SARS-CoV-2 Detection. <i>Micromachines</i> , 2022, 13, 196.	2.9	16
786	Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. <i>BMC Molecular and Cell Biology</i> , 2022, 23, 2.	2.0	10
787	Recombinant human interferon- λ 1b inhibits SARS-CoV-2 better than interferon- λ 2b in vitro. <i>Virologica Sinica</i> , 2022, , .	3.0	1
788	Immunity evasion: consequence of the N501Y mutation of the SARS-CoV-2 spike glycoprotein. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 10.	3.3	7
790	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	7.0	144
791	The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 18.	17.1	9
792	Interoperability of COVID-19 Clinical Phenotype Data with Host and Viral Genetics Data. <i>BioMed</i> , 2022, 2, 69-81.	1.1	3
794	Evidence of a SARS-CoV-2 double Spike mutation D614G/S939F potentially affecting immune response of infected subjects. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 733-744.	4.1	6
795	Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift. <i>Journal of Medical Virology</i> , 2022, , .	5.0	5
796	Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 230.	3.3	1
797	Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding. <i>Viruses</i> , 2022, 14, 295.	3.3	12
799	Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry. <i>Angewandte Chemie</i> , 2022, 0, , .	2.0	0
801	Variant analysis of SARS-CoV-2 strains with phylogenetic analysis and the Coronavirus Antiviral and Resistance Database. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 157-167.	1.4	2

#	ARTICLE	IF	CITATIONS
802	Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	13.8	19
803	HBD-2 binds SARS-CoV-2 RBD and blocks viral entry: Strategy to combat COVID-19. <i>IScience</i> , 2022, 25, 103856.	4.1	23
804	In Planta Production of the Receptor-Binding Domain From SARS-CoV-2 With Human Blood Group A Glycan Structures. <i>Frontiers in Chemistry</i> , 2021, 9, 816544.	3.6	7
805	Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS-CoV-2 Variants after Primary and Booster Immunization. <i>International Journal of Infectious Diseases</i> , 2022, 117, 97-102.	3.3	5
806	Designed SARS-CoV-2 receptor binding domain variants form stable monomers. <i>Biotechnology Journal</i> , 2022, 17, e2100422.	3.5	8
807	Quantifying the effect of government interventions and virus mutations on transmission advantage during COVID-19 pandemic. <i>Journal of Infection and Public Health</i> , 2022, 15, 338-342.	4.1	6
808	SARS-CoV-2 in Egypt: epidemiology, clinical characterization and bioinformatics analysis. <i>Heliyon</i> , 2022, 8, e08864.	3.2	2
809	Highlight of potential impact of new viral genotypes of SARS-CoV-2 on vaccines and anti-viral therapeutics. <i>Gene Reports</i> , 2022, 26, 101537.	0.8	3
810	Early introduction, dispersal and evolution of Delta SARS-CoV-2 in Southern Brazil, late predominance of AY.99.2 and AY.101 related lineages. <i>Virus Research</i> , 2022, 311, 198702.	2.2	15
811	The Influence of New SARS-CoV-2 Variant Omicron (B.1.1.529) on Vaccine Efficacy, its Correlation to Delta Variants: A Computational Approach. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
812	Mutations in human SARS-CoV-2 spike proteins, potential drug binding and epitope sites for COVID-19 therapeutics development. <i>Current Research in Structural Biology</i> , 2022, 4, 41-50.	2.2	25
813	Virus-specific editing identification approach reveals the landscape of A-to-I editing and its impacts on SARS-CoV-2 characteristics and evolution. <i>Nucleic Acids Research</i> , 2022, 50, 2509-2521.	14.5	23
814	Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. <i>Nature Communications</i> , 2022, 13, 688.	12.8	23
818	Persistent SARS-CoV-2 Infection in a Patient With Non-hodgkin Lymphoma: Intra-Host Genomic Diversity Analysis. <i>Frontiers in Virology</i> , 2022, 2, .	1.4	4
819	Genome sequence analysis of SARS-COV-2 isolated from a COVID-19 patient in Erbil, Iraq. <i>Applied Nanoscience (Switzerland)</i> , 2022, , 1-7.	3.1	2
820	Rapid detection of multiple SARS-CoV-2 variants of concern by PAM-targeting mutations. <i>Cell Reports Methods</i> , 2022, 2, 100173.	2.9	12
821	Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka. <i>Wellcome Open Research</i> , 0, 6, 110.	1.8	4
822	Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review. <i>Viruses</i> , 2022, 14, 351.	3.3	11

#	ARTICLE	IF	CITATIONS
823	Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants. <i>Advanced Science</i> , 2022, 9, e2105378.	11.2	12
824	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	4.8	73
825	Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. <i>Cell</i> , 2022, 185, 485-492.e10.	28.9	38
826	Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	26
827	An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 44.	17.1	31
829	The variants of SARS-CoV-2 and the challenges of vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 1366-1372.	5.0	29
830	Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa. <i>Journal of Medical Virology</i> , 2022, 94, 1728-1733.	5.0	193
831	COVID-19: comprehensive review on mutations and current vaccines. <i>Archives of Microbiology</i> , 2022, 204, 8.	2.2	26
832	Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. <i>Infection</i> , 2022, 50, 309-325.	4.7	112
833	The emergence, genomic diversity and global spread of SARS-CoV-2. <i>Nature</i> , 2021, 600, 408-418.	27.8	249
834	A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	58
837	Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. <i>ELife</i> , 2021, 10, .	6.0	29
840	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. <i>International Journal of Biological Sciences</i> , 2022, 18, 1844-1851.	6.4	34
841	Insights from computational analysis: how does the SARS-CoV-2 Delta (B.1.617.2) variant hijack ACE2 more effectively?. <i>Physical Chemistry Chemical Physics</i> , 2022, , .	2.8	7
842	Both simulation and sequencing data reveal coinfections with multiple SARS-CoV-2 variants in the COVID-19 pandemic. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1389-1401.	4.1	7
843	Molecular Study for Mutation of N-gene and S-gene COVID-19 Virus. <i>International Journal for Research in Applied Sciences and Biotechnology</i> , 2022, 9, 34-44.	0.3	1
844	Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. <i>Theranostics</i> , 2022, 12, 2519-2534.	10.0	3
845	Origin of the tight binding mode to ACE2 triggered by multi-point mutations in the omicron variant: a dynamic insight. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 8724-8737.	2.8	11

#	ARTICLE	IF	CITATIONS
846	Tetra-primer ARMS-PCR combined with dual-color fluorescent lateral flow assay for the discrimination of SARS-CoV-2 and its mutations with a handheld wireless reader. Lab on A Chip, 2022, 22, 1531-1541.	6.0	15
848	High diversity in Delta variant across countries revealed by genome-wide analysis of SARS-CoV-2 beyond the Spike protein. Molecular Systems Biology, 2022, 18, e10673.	7.2	18
850	Comparison of Chest Computed Tomography Between the Two Waves of Coronavirus Disease 2019 in Belgium Using Artificial Intelligence. Cureus, 2022, 14, e22203.	0.5	0
851	Phage-Displayed Mimotopes of SARS-CoV-2 Spike Protein Targeted to Authentic and Alternative Cellular Receptors. Viruses, 2022, 14, 384.	3.3	10
852	A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice. Journal of Virology, 2022, 96, JVI0157821.	3.4	14
853	Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant. Frontiers in Microbiology, 2022, 13, 845316.	3.5	8
855	Omicron variant losing its critical mutations in the receptor-binding domain. Journal of Medical Virology, 2022, 94, 2365-2368.	5.0	7
856	Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections. Frontiers in Immunology, 2022, 13, 773652.	4.8	9
857	Strikingly Different Roles of SARS-CoV-2 Fusion Peptides Uncovered by Neutron Scattering. Journal of the American Chemical Society, 2022, 144, 2968-2979.	13.7	30
858	An engineered bispecific human monoclonal antibody against SARS-CoV-2. Nature Immunology, 2022, 23, 423-430.	14.5	38
859	The relevant information about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the five-question approach (when, where, what, why, and how) and its impact on the environment. Environmental Science and Pollution Research, 2023, 30, 61430-61454.	5.3	6
860	Analyses of Long-Term Epidemic Trends and Evolution Characteristics of Haplotype Subtypes Reveal the Dynamic Selection on SARS-CoV-2. Viruses, 2022, 14, 454.	3.3	2
861	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. Medical Review, 2022, 2, 3-22.	1.2	7
862	SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. Frontiers in Medicine, 2022, 9, 815389.	2.6	96
863	Inhibition of Protein N-Glycosylation Blocks SARS-CoV-2 Infection. MBio, 2022, 13, e0371821.	4.1	24
864	SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes. Microbiology Spectrum, 2022, 10, e0022122.	3.0	10
866	Tracking the transmission dynamics of COVID-19 with a time-varying coefficient state-space model. Statistics in Medicine, 2022, 41, 2745-2767.	1.6	6
867	SARS-CoV-2 variants and spike mutations involved in second wave of COVID-19 pandemic in India. Transboundary and Emerging Diseases, 2022, 69, .	3.0	7

#	ARTICLE	IF	CITATIONS
868	EvoRator: Prediction of Residue-level Evolutionary Rates from Protein Structures Using Machine Learning. <i>Journal of Molecular Biology</i> , 2022, 434, 167538.	4.2	4
870	Profiling of the most reliable mutations from sequenced SARS-CoV-2 genomes scattered in Uzbekistan. <i>PLoS ONE</i> , 2022, 17, e0266417.	2.5	7
871	Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization. <i>Frontiers in Immunology</i> , 2022, 13, 836232.	4.8	15
872	The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. <i>Emerging Microbes and Infections</i> , 2022, 11, 793-803.	6.5	14
873	Engineering Strategies to Overcome the Stability–Function Trade-Off in Proteins. <i>ACS Synthetic Biology</i> , 2022, 11, 1030-1039.	3.8	15
874	Clinico-Genomic Analysis Reiterates Mild Symptoms Post-vaccination Breakthrough: Should We Focus on Low-Frequency Mutations?. <i>Frontiers in Microbiology</i> , 2022, 13, 763169.	3.5	3
875	Comprehensive compartmental model and calibration algorithm for the study of clinical implications of the population-level spread of COVID-19: a study protocol. <i>BMJ Open</i> , 2022, 12, e052681.	1.9	3
877	CovDif, a Tool to Visualize the Conservation between SARS-CoV-2 Genomes and Variants. <i>Viruses</i> , 2022, 14, 561.	3.3	1
878	Impact of the SARS-CoV-2 Delta Variant on the Psychological States and Health-Related Quality of Life in Patients With Crohn’s Disease. <i>Frontiers in Medicine</i> , 2022, 9, 795889.	2.6	1
879	Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell entry process, and cytokine storm in COVID-19. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 964-986.	2.6	8
880	Role of the Microbiome in the Pathogenesis of COVID-19. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 736397.	3.9	17
881	New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression. <i>Journal of Medical Virology</i> , 2022, 94, 3112-3120.	5.0	12
882	Targeted Sanger sequencing to recover key mutations in SARS-CoV-2 variant genome assemblies produced by next-generation sequencing. <i>Microbial Genomics</i> , 2022, 8, .	2.0	7
883	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	4.1	117
884	Antibody escape and global spread of SARS-CoV-2 lineage A.27. <i>Nature Communications</i> , 2022, 13, 1152.	12.8	20
885	Mutations in the genome of severe acute respiratory syndrome coronavirus 2: implications for COVID-19 severity and progression. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210864.	1.0	5
886	35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope. <i>Cell Host and Microbe</i> , 2022, 30, 887-895.e4.	11.0	20
887	SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments. <i>Therapeutic Delivery</i> , 2022, 13, 187-203.	2.2	8

#	ARTICLE	IF	CITATIONS
889	The Runaway Evolution of SARS-CoV-2 Leading to the Highly Evolved Delta Strain. <i>Molecular Biology and Evolution</i> , 2022, 39, .	8.9	14
890	The evolution of SARS-CoV-2 variants and their clinical and healthcare implications. <i>Revista Cl&#x00ed;nica Espan&#x00f5;la</i> , 2022, , .	0.5	1
891	Association of viral load with age, gender, disease severity, and death in severe acute respiratory syndrome coronavirus 2 variants. <i>Journal of Medical Virology</i> , 2022, 94, 3063-3069.	5.0	7
892	Tracking SARS-CoV-2 Mutations & Variants Through the COG-UK-Mutation Explorer. <i>Virus Evolution</i> , 2022, 8, veac023.	4.9	19
893	The N1038S Substitution and 1153EQTRPKSV1162 Deletion of the S2 Subunit of QX-Type Avian Infectious Bronchitis Virus Can Synergistically Enhance Viral Proliferation. <i>Frontiers in Microbiology</i> , 2022, 13, 829218.	3.5	2
894	The inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein. <i>ELife</i> , 2022, 11, .	6.0	40
895	Rapid and parallel adaptive mutations in spike S1 drive clade success in SARS-CoV-2. <i>Cell Host and Microbe</i> , 2022, 30, 545-555.e4.	11.0	59
896	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. <i>Frontiers in Immunology</i> , 2022, 13, 773982.	4.8	10
897	Injectable Slow-Release Hydrogel Formulation of a Plant Virus-Based COVID-19 Vaccine Candidate. <i>Biomacromolecules</i> , 2022, 23, 1812-1825.	5.4	20
898	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	6.1	23
899	Design of SARS-CoV-2 Variant-Specific PCR Assays Considering Regional and Temporal Characteristics. <i>Applied and Environmental Microbiology</i> , 2022, 88, e0228921.	3.1	12
901	Genomic Surveillance of COVID-19 Variants With Language Models and Machine Learning. <i>Frontiers in Genetics</i> , 2022, 13, 858252.	2.3	8
902	Molecular epidemiological features of SARS-CoV-2 in Japan, 2020â€“1. <i>Virus Evolution</i> , 2022, 8, veac034.	4.9	9
903	Mutational scanning of spike RBD protein for enhanced ACE2 affinity emerging Southeast Asia in the late transmission phase. <i>Scientific Reports</i> , 2022, 12, 5896.	3.3	3
904	Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, 1788.	12.8	30
906	A New Wave of COVID-19 in 2021 with Unique Genetic Characters - Present Global Scenario and Beholding Onwards. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.8	4
907	The basis of mink susceptibility to SARS-CoV-2 infection. <i>Journal of Applied Genetics</i> , 2022, 63, 543-555.	1.9	5
908	Direct comparison of RT-ddPCR and targeted amplicon sequencing for SARS-CoV-2 mutation monitoring in wastewater. <i>Science of the Total Environment</i> , 2022, 833, 155059.	8.0	29

#	ARTICLE	IF	CITATIONS
909	Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models. <i>Science Translational Medicine</i> , 2022, 14, eabm0899.	12.4	68
910	Dynamic Ca ²⁺ sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry. <i>Cell Reports</i> , 2022, 39, 110694.	6.4	19
911	MutCov: A pipeline for evaluating the effect of mutations in spike protein on infectivity and antigenicity of SARS-CoV-2. <i>Computers in Biology and Medicine</i> , 2022, 145, 105509.	7.0	2
912	Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell fusion, and neutralization sensitivity. <i>Emerging Microbes and Infections</i> , 2022, 11, 1024-1036.	6.5	5
913	Evaluation of binding performance of bioactive compounds against main protease and mutant model spike receptor binding domain of SARS-CoV-2: Docking, ADMET properties and molecular dynamics simulation study. <i>Journal of the Indian Chemical Society</i> , 2022, 99, 100417.	2.8	8
914	Simple Formulae, Deep Learning and Elaborate Modelling for the COVID-19 Pandemic. <i>Encyclopedia</i> , 2022, 2, 679-689.	4.5	1
916	Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112802.	5.6	5
917	Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. <i>Microbiological Research</i> , 2022, 258, 126993.	5.3	22
918	Emergence of SARS-CoV-2 Alpha lineage and its correlation with quantitative wastewater-based epidemiology data. <i>Water Research</i> , 2022, 215, 118257.	11.3	17
919	MXene nanosheets as a novel nanomaterial with antimicrobial applications: A literature review. <i>Journal of Molecular Structure</i> , 2022, 1262, 132958.	3.6	9
920	Next Generation Sequence Prediction Intelligent System for SARS-COV-2 Using Deep Learning Neural Network. , 2021, , .		5
921	Estimating the transmission advantage of the D614G mutant strain of SARS-CoV-2, December 2019 to June 2020. <i>Eurosurveillance</i> , 2021, 26, .	7.0	16
923	Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays. <i>Viruses</i> , 2022, 14, 69.	3.3	5
924	Hotspots for mutations in the SARS-CoV-2 spike glycoprotein: a correspondence analysis. <i>Scientific Reports</i> , 2021, 11, 23622.	3.3	9
925	SARS-CoV-2 Variant Screening Using a Virus-Receptor-Based Electrical Biosensor. <i>Nano Letters</i> , 2022, 22, 50-57.	9.1	28
926	SARS-CoV-2 Therapeutic Landscape, Opportunity and Future Threats. <i>The Open Covid Journal</i> , 2021, 1, 205-215.	0.2	0
927	Development of an efficient Sanger sequencing-based assay for detecting SARS-CoV-2 spike mutations. <i>PLoS ONE</i> , 2021, 16, e0260850.	2.5	11
928	Modeling the onset of symptoms of COVID-19: Effects of SARS-CoV-2 variant. <i>PLoS Computational Biology</i> , 2021, 17, e1009629.	3.2	17

#	ARTICLE	IF	CITATIONS
929	Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 763460.	4.8	16
930	COVID-19 pandemisinin ilk yÄ±lÄ±nda Å¶ÄŸrendiklerimiz. <i>Hitit Medical Journal</i> ;, 0, , .	2.0	0
931	Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells. <i>MAbs</i> , 2022, 14, 2005507.	5.2	8
932	Mutational landscape of SARS-CoV-2 genome in Turkey and impact of mutations on spike protein structure. <i>PLoS ONE</i> , 2021, 16, e0260438.	2.5	6
934	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	1.7	27
935	Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab626.	0.9	6
936	Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies. <i>Vaccines</i> , 2022, 10, 23.	4.4	37
937	Viral surface geometry shapes influenza and coronavirus spike evolution through antibody pressure. <i>PLoS Computational Biology</i> , 2021, 17, e1009664.	3.2	4
938	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	3.4	26
941	State-of-the-art preclinical evaluation of COVID-19 vaccine candidates. <i>Exploration of Immunology</i> , 0, , 440-460.	0.3	0
942	Impact of SARS-CoV-2 Mutations on Global Travel and the Increasing Number of Re-Infections: A Risk-Assessment Perspective. <i>The Open Covid Journal</i> , 2021, 1, 196-204.	0.2	2
943	Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro. <i>EBioMedicine</i> , 2021, 74, 103712.	6.1	37
944	Genetic Drift Versus Climate Region Spreading Dynamics of COVID-19. <i>Frontiers in Genetics</i> , 2021, 12, 663371.	2.3	3
945	SARS-CoV-2 mutations acquired during serial passage in human cell lines are consistent with several of those found in recent natural SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1925-1934.	4.1	16
946	Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis. <i>Scientific Reports</i> , 2022, 12, 6241.	3.3	12
947	Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. <i>Viruses</i> , 2022, 14, 827.	3.3	14
948	The Delta SARS-CoV-2 Variant of Concern Induces Distinct Pathogenic Patterns of Respiratory Disease in K18-hACE2 Transgenic Mice Compared to the Ancestral Strain from Wuhan. <i>MBio</i> , 2022, 13, e0068322.	4.1	17
949	Variant Analysis and Strategic Clustering to Sub-Lineage of Double Mutant Strain B.1.617 of SARS-CoV-2. <i>Covid</i> , 2022, 2, 513-531.	1.5	1

#	ARTICLE	IF	CITATIONS
950	Modeling the evolution of SARS-CoV-2 under non-pharmaceutical interventions and testing. <i>Evolution, Medicine and Public Health</i> , 2022, 10, 179-188.	2.5	7
951	Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma. <i>Advanced Science</i> , 2022, 9, e2104333.	11.2	8
952	Transient Expression of Glycosylated SARS-CoV-2 Antigens in <i>Nicotiana benthamiana</i> . <i>Plants</i> , 2022, 11, 1093.	3.5	12
953	Preclinical study of a DNA vaccine targeting SARS-CoV-2. <i>Current Research in Translational Medicine</i> , 2022, 70, 103348.	1.8	9
954	SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't. <i>Journal of Neural Transmission</i> , 2022, 129, 1155-1167.	2.8	19
955	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
956	SARS-CoV-2: Evolution and Emergence of New Viral Variants. <i>Viruses</i> , 2022, 14, 653.	3.3	39
957	Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2. <i>Methods in Molecular Biology</i> , 2022, 2452, 361-378.	0.9	1
958	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
959	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. <i>Frontiers in Immunology</i> , 2022, 13, 804945.	4.8	12
960	A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 702.	4.4	18
961	Detection of Major SARS-CoV-2 Variants of Concern in Clinical Samples via CRISPR-Cas12a-Mediated Mutation-Specific Assay. <i>ACS Synthetic Biology</i> , 2022, 11, 1811-1823.	3.8	9
962	Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent. <i>Future Virology</i> , 2022, 17, 403-413.	1.8	6
963	The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. <i>Vaccines</i> , 2022, 10, 712.	4.4	4
964	Identification and Analysis of SARS-CoV-2 Alpha Variants in the Largest Taiwan COVID-19 Outbreak in 2021. <i>Frontiers in Medicine</i> , 2022, 9, 869818.	2.6	10
965	Tracking SARS-CoV-2 Omicron diverse spike gene mutations identifies multiple inter-variant recombination events. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 138.	17.1	140
966	Genetic differentiation and diversity of SARS-CoV-2 Omicron variant in its early outbreak. <i>Biosafety and Health</i> , 2022, 4, 171-178.	2.7	11
967	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	28.9	77

#	ARTICLE	IF	CITATIONS
968	Probing the Immune System Dynamics of the COVID-19 Disease for Vaccine Designing and Drug Repurposing Using Bioinformatics Tools. <i>Immuno</i> , 2022, 2, 344-371.	1.5	2
969	Comprehensive role of SARS-CoV-2 spike glycoprotein in regulating host signaling pathway. <i>Journal of Medical Virology</i> , 2022, 94, 4071-4087.	5.0	5
970	Unique Aggregation of Retroviral Particles Pseudotyped with the Delta Variant SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2022, 14, 1024.	3.3	2
971	Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic. <i>PLoS ONE</i> , 2022, 17, e0267847.	2.5	20
972	Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. <i>JAMA Network Open</i> , 2022, 5, e2210780.	5.9	27
973	Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients. <i>Communications Biology</i> , 2022, 5, 409.	4.4	5
974	SARS-CoV-2 variants – Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579.	3.1	26
975	Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts. <i>Microbiology Spectrum</i> , 2022, 10, e0079122.	3.0	19
976	Massively multiplexed affinity characterization of therapeutic antibodies against SARS-CoV-2 variants. <i>Antibody Therapeutics</i> , 2022, 5, 130-137.	1.9	5
977	nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. <i>Dr Sulaiman Al Habib Medical Journal</i> , 0, , 1.	0.8	0
978	Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern. <i>Virology</i> , 2022, 572, 44-54.	2.4	21
979	SARS-CoV-2 Lineage A.27: New Data from African Countries and Dynamics in the Context of the COVID-19 Pandemic. <i>Viruses</i> , 2022, 14, 1007.	3.3	5
980	Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions. <i>Annals of Medicine and Surgery</i> , 2022, 78, 103737.	1.1	33
981	Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins. <i>Antiviral Research</i> , 2022, 203, 105332.	4.1	2
982	The Primacy of Moringa (<i>Moringa oleifera</i> Lam.) in Boosting Nutrition Status and Immunity Defence Amidst the COVID-19 Catastrophe: A Perspective. <i>Phyton</i> , 2022, 91, 1831-1858.	0.7	1
983	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	14.3	74
984	Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination. <i>JCI Insight</i> , 2022, 7, .	5.0	13
985	NGS data vectorization, clustering, and finding key codons in SARS-CoV-2 variations. <i>BMC Bioinformatics</i> , 2022, 23, 187.	2.6	2

#	ARTICLE	IF	CITATIONS
986	Evolution of the SARS-CoV-2 pandemic in India. Medical Journal Armed Forces India, 2022, 78, 264-270.	0.8	7
987	Analysis of the evolution, infectivity and antigenicity of circulating rabies virus strains. Emerging Microbes and Infections, 2022, 11, 1474-1487.	6.5	6
988	An Electrostatically-steered Conformational Selection Mechanism Promotes SARS-CoV-2 Spike Protein Variation. Journal of Molecular Biology, 2022, 434, 167637.	4.2	1
989	Bioinformatics for the Origin and Evolution of Viruses. Advances in Experimental Medicine and Biology, 2022, 1368, 53-71.	1.6	2
990	Studying bona fide SARS-CoV-2 biology in a BSL-2 biosafety environment using a split-virus-genome system. Science China Life Sciences, 2022, 65, 1894-1897.	4.9	2
991	High prevalence of an alpha variant lineage with a premature stop codon in ORF7a in Iraq, winter 2020â€“2021. PLoS ONE, 2022, 17, e0267295.	2.5	8
993	Detecting Potentially Adaptive Mutations from the Parallel and Fixed Patterns in SARS-CoV-2 Evolution. Viruses, 2022, 14, 1087.	3.3	4
994	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. Frontiers in Medicine, 2022, 9, .	2.6	43
995	Human interaction targets of SARS-CoV-2 spike protein: A systematic review. European Journal of Inflammation, 2022, 20, 1721727X2210953.	0.5	3
996	Detection of SARS-CoV-2 Delta Variant of Concern AY.57 and Clinical Characteristics of Imported Cases on a Vietnamese Coal Carrier Vessel in East Kalimantan, Indonesia: A Case Report. Jurnal Respirasi, 2022, 8, 99-105.	0.2	0
997	Investigation and Comparison of Specific Antibodiesâ€™ Affinity Interaction with SARS-CoV-2 Wild-Type, B.1.1.7, and B.1.351 Spike Protein by Total Internal Reflection Ellipsometry. Biosensors, 2022, 12, 351.	4.7	14
998	Transmission of SARS-CoV-2 from humans to animals and potential host adaptation. Nature Communications, 2022, 13, .	12.8	67
999	Microbial ecology and evolution is key to pandemics: using the coronavirus model to mitigate future public health challenges. Heliyon, 2022, 8, e09449.	3.2	3
1000	Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination. Nature Communications, 2022, 13, .	12.8	12
1001	Real-time allelic assays of SARS-CoV-2 variants to enhance sewage surveillance. Water Research, 2022, 220, 118686.	11.3	17
1002	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. International Reviews of Immunology, 2023, 42, 393-414.	3.3	26
1003	Nanomechanical assay for ultrasensitive and rapid detection of SARS-CoV-2 based on peptide nucleic acid. Nano Research, 2023, 16, 1183-1195.	10.4	6
1004	A Multivalent Vaccine Based on Ferritin Nanocage Elicits Potent Protective Immune Responses against SARS-CoV-2 Mutations. International Journal of Molecular Sciences, 2022, 23, 6123.	4.1	9

#	ARTICLE	IF	CITATIONS
1005	Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	24
1006	SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. <i>Small</i> , 2022, 18, .	10.0	11
1008	Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies. <i>Cell Discovery</i> , 2022, 8, .	6.7	40
1009	Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape. <i>PLoS Computational Biology</i> , 2022, 18, e1010160.	3.2	14
1010	The past, current and future epidemiological dynamic of SARS-CoV-2. <i>Oxford Open Immunology</i> , 2022, 3, .	2.8	24
1012	SARS-CoV-2 intra-host evolution during prolonged infection in an immunocompromised patient. <i>International Journal of Infectious Diseases</i> , 2022, 122, 444-448.	3.3	22
1013	Early Oxygen Treatment Measurements Can Predict COVID-19 Mortality: A Preliminary Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 1146.	2.0	0
1014	The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach. <i>Microbial Pathogenesis</i> , 2022, 169, 105619.	2.9	4
1015	Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. <i>Transfusion Medicine Reviews</i> , 2022, 36, 125-132.	2.0	8
1016	Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6394.	4.1	17
1017	From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1704-1714.	5.2	15
1018	Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines. <i>Med</i> , 2022, , .	4.4	2
1019	A Rapid, Whole Genome Sequencing Assay for Detection and Characterization of Novel Coronavirus (SARS-CoV-2) Clinical Specimens Using Nanopore Sequencing. <i>Frontiers in Microbiology</i> , 0, 13, .	3.5	4
1020	Understanding the mutational frequency in SARS-CoV-2 proteome using structural features. <i>Computers in Biology and Medicine</i> , 2022, 147, 105708.	7.0	6
1021	Nanotechnology: New frontiers in anti-HIV therapy. , 2022, , 129-171.		0
1023	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	59
1024	Identification of SARS-CoV-2 Variants of Concern Using Amplicon Next-Generation Sequencing. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	10
1025	Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study. <i>BMC Infectious Diseases</i> , 2022, 22, .	2.9	9

#	ARTICLE	IF	CITATIONS
1026	Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 6064-6073.	4.6	14
1027	The Cholesterol-Binding Sequence in Monomeric C-Reactive Protein Binds to the SARS-CoV-2 Spike Receptor-Binding Domain and Blocks Interaction With Angiotensin-Converting Enzyme 2. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
1029	Raman Fingerprints of the SARS-CoV-2 Delta Variant and Mechanisms of Its Instantaneous Inactivation by Silicon Nitride Bioceramics. <i>ACS Infectious Diseases</i> , 2022, 8, 1563-1581.	3.8	7
1030	A smartphone-based platform for ratiometric visualization of SARS-CoV-2 via an oligonucleotide probe. <i>Mikrochimica Acta</i> , 2022, 189, .	5.0	6
1031	Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. <i>Viruses</i> , 2022, 14, 1560.	3.3	21
1032	Trimeric receptor-binding domain of SARS-CoV-2 acts as a potent inhibitor of ACE2 receptor-mediated viral entry. <i>IScience</i> , 2022, 25, 104716.	4.1	6
1033	Rapid and Affordable High Throughput Screening of SARS-CoV-2 Variants Using Denaturing High-Performance Liquid Chromatography Analysis. <i>Frontiers in Virology</i> , 0, 2, .	1.4	0
1034	Identification of Surface Glycoprotein Mutations of SARS-CoV-2 in Isolated Strains from Iraq. <i>Medical Immunology (Russia)</i> , 2022, 24, 729-740.	0.4	2
1035	Characterization and Utilization of Disulfide-Bonded SARS-CoV-2 Receptor Binding Domain of Spike Protein Synthesized by Wheat Germ Cell-Free Production System. <i>Viruses</i> , 2022, 14, 1461.	3.3	3
1036	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	6
1038	Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications. <i>Journal of Clinical Immunology</i> , 2022, 42, 1371-1378.	3.8	11
1039	Functional mutations of SARS-CoV-2: implications to viral transmission, pathogenicity and immune escape. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	2.3	3
1041	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	8
1042	SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron. <i>Emerging Microbes and Infections</i> , 2022, 11, 1819-1827.	6.5	10
1043	Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
1044	Multifaceted Assessment of Wastewater-Based Epidemiology for SARS-CoV-2 in Selected Urban Communities in Davao City, Philippines: A Pilot Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8789.	2.6	5
1045	Insight into Genetic Characteristics of Identified SARS-CoV-2 Variants in Egypt from March 2020 to May 2021. <i>Pathogens</i> , 2022, 11, 834.	2.8	9
1046	Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8177.	4.1	5

#	ARTICLE	IF	CITATIONS
1047	Nanosponges: An overlooked promising strategy to combat SARS-CoV-2. Drug Discovery Today, 2022, 27, 103330.	6.4	6
1048	Perspective Chapter: Bioinformatics Study of the Evolution of SARS-CoV-2 Spike Protein. Infectious Diseases, 0, , .	4.0	0
1049	Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy. Frontiers in Microbiology, 0, 13, .	3.5	10
1050	Sequence Similarity Network Analysis Provides Insight into the Temporal and Geographical Distribution of Mutations in SARS-CoV-2 Spike Protein. Viruses, 2022, 14, 1672.	3.3	0
1051	Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus Evolution, 2022, 8, .	4.9	53
1052	Immunological and Pathological Peculiarity of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant. Microbiology Spectrum, 2022, 10, .	3.0	2
1053	Missense mutations in spike protein of SARS-CoV-2 delta variant contribute to the alteration in viral structure and interaction with hACE2 receptor. Immunity, Inflammation and Disease, 2022, 10, .	2.7	6
1054	Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies. Communications Biology, 2022, 5, .	4.4	5
1055	SARS-CoV-2 vaccine-induced antibody and T cell response in SARS-CoV-1 survivors. Cell Reports, 2022, 40, 111284.	6.4	4
1056	The Microalgal Diatoxanthin Inflects the Cytokine Storm in SARS-CoV-2 Stimulated ACE2 Overexpressing Lung Cells. Antioxidants, 2022, 11, 1515.	5.1	5
1057	Evolutionary remodelling of N-terminal domain loops fine-tunes SARS-CoV-2 spike. EMBO Reports, 2022, 23, .	4.5	18
1058	Insights into the microevolution of SARS-ACE2 interactions: in silico analysis of glycosylation and SNP pattern. Journal of Biomolecular Structure and Dynamics, 2023, 41, 6442-6449.	3.5	3
1059	Uninvited Guest: Arrival and Dissemination of Omicron Lineage SARS-CoV-2 in St. Petersburg, Russia. Microorganisms, 2022, 10, 1676.	3.6	5
1061	Emergence and Spread of the SARS-CoV-2 Variant of Concern Delta across Different Brazilian Regions. Microbiology Spectrum, 2022, 10, .	3.0	9
1062	Reconsidering the need for gain-of-function research on enhanced potential pandemic pathogens in the post-COVID-19 era. Frontiers in Bioengineering and Biotechnology, 0, 10, .	4.1	2
1063	The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	11
1064	Multi-task learning for predicting SARS-CoV-2 antibody escape. Frontiers in Genetics, 0, 13, .	2.3	1
1065	Prediction of infectivity of SARS-CoV-2 virus based on Spike-hACE-2 interaction. VirusDisease, 0, , .	2.0	0

#	ARTICLE	IF	CITATIONS
1066	The Experience of COVID-19: Variants, Vaccines and Policies. , 0, 8, 230-235.		0
1067	Core fucoseâ€specific <i>Pholiota squarrosa</i> lectin (<scp>PhoSL</scp>) as a potent broadâ€spectrum inhibitor of <scp>SARSâ€CoV</scp>â€2 infection. FEBS Journal, 2023, 290, 412-427.	4.7	4
1068	Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design. Scientific Reports, 2022, 12, .	3.3	6
1069	Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naÃve hamsters compared to ancestral vaccine. EBioMedicine, 2022, 83, 104196.	6.1	26
1070	Sequencing and mutations analysis of the first recorded SARS-CoV-2 Omicron variant during the fourth wave of pandemic in Iraq. Brazilian Journal of Infectious Diseases, 2022, 26, 102677.	0.6	2
1071	Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. IScience, 2022, 25, 104886.	4.1	5
1072	Selective reversed-phase high-performance liquid chromatography method for the determination of intact SARS-CoV-2 spike protein. Journal of Chromatography A, 2022, 1680, 463424.	3.7	2
1073	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. Biomedicine and Pharmacotherapy, 2022, 154, 113522.	5.6	56
1075	Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	7
1076	Systematic analysis and comparison of O-glycosylation of five recombinant spike proteins in Î2-coronaviruses. Analytica Chimica Acta, 2022, 1230, 340394.	5.4	2
1077	Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening. Virus Research, 2022, 321, 198915.	2.2	2
1078	Nanozyme-strip for rapid and ultrasensitive nucleic acid detection of SARS-CoV-2. Biosensors and Bioelectronics, 2022, 217, 114739.	10.1	25
1079	Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2. , 2022, , 161-181.		0
1080	RBD spatial orientation of the spike protein and its binding to ACE2: insight into the high infectivity of the SARS-CoV-2 Delta variant from MD simulations. Physical Chemistry Chemical Physics, 0, , .	2.8	2
1081	Smart Door System for Maintaining Social Distancing and Controlling Spread of Infectious Disease. Lecture Notes in Electrical Engineering, 2022, , 527-537.	0.4	0
1082	Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology, 2022, , 1-69.	2.2	12
1083	Precision Medicine in Infectious Disease. , 2022, , 221-257.		2
1084	Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	7

#	ARTICLE	IF	CITATIONS
1085	SARS-CoV-2 Genetic Diversity and Lineage Dynamics in Egypt during the First 18 Months of the Pandemic. <i>Viruses</i> , 2022, 14, 1878.	3.3	4
1086	Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2. <i>Journal of Microbiology and Biotechnology</i> , 2022, 32, 1073-1085.	2.1	2
1087	Broad-spectrum antiviral activity of <i>Spatholobus suberectus</i> Dunn against SARS-CoV-2, SARS-CoV-1, H5N1, and other enveloped viruses. <i>Phytotherapy Research</i> , 2022, 36, 3232-3247.	5.8	12
1088	Whole genome sequencing analysis of SARS-CoV-2 from Malaysia: From alpha to Omicron. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	5
1089	African Swine Fever Vaccinology: The Biological Challenges from Immunological Perspectives. <i>Viruses</i> , 2022, 14, 2021.	3.3	12
1090	Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
1091	Retrospective Cohort Study of COVID-19 in Patients of the Brazilian Public Health System with SARS-CoV-2 Omicron Variant Infection. <i>Vaccines</i> , 2022, 10, 1504.	4.4	2
1092	Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation. <i>Vaccine</i> , 2022, , .	3.8	3
1093	Molecular Mechanism of the Non-Covalent Orally Targeted SARS-CoV-2 M ^{pro} Inhibitor S-217622 and Computational Assessment of Its Effectiveness against Mainstream Variants. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 8893-8901.	4.6	7
1094	Evolution of SARS-CoV-2 during the first year of the COVID-19 pandemic in Northwestern Argentina. <i>Virus Research</i> , 2023, 323, 198936.	2.2	5
1095	NanoCoV19: An analytical pipeline for rapid detection of severe acute respiratory syndrome coronavirus 2. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	2
1096	Pathogenetic Mechanisms Of Dry Eye Syndrome In A Novel Coronavirus Infection Caused By SARS-CoV-2. <i>Russian Open Medical Journal</i> , 2022, 11, .	0.3	0
1097	Quantifying Mutational Response to Track the Evolution of SARS-CoV-2 Spike Variants: Introducing a Statistical-Mechanics-Guided Machine Learning Method. <i>Journal of Physical Chemistry B</i> , 2022, 126, 7895-7905.	2.6	5
1098	Biophysical and Biochemical Characterization of the Receptor Binding Domain of SARS-CoV-2 Variants. <i>Protein Journal</i> , 2022, 41, 457-467.	1.6	0
1099	Molecular modelling on multiepitope-based vaccine against SARS-CoV-2 using immunoinformatics, molecular docking, and molecular dynamics simulation. <i>SAR and QSAR in Environmental Research</i> , 2022, 33, 649-675.	2.2	3
1100	Preexisting antibodies targeting SARS-CoV-2 S2 cross-react with commensal gut bacteria and impact COVID-19 vaccine induced immunity. <i>Gut Microbes</i> , 2022, 14, .	9.8	8
1102	COVID-19 Positive Status is Associated with Increased In-hospital Mortality in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-analysis. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 17-24.	0.8	2
1103	Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy. <i>Microbiology Spectrum</i> , 0, , .	3.0	0

#	ARTICLE	IF	CITATIONS
1104	Novel skewed usage of B-cell receptors in COVID-19 patients with various clinical presentations. Immunology Letters, 2022, 249, 23-32.	2.5	4
1105	Structural heterogeneity and precision of implications drawn from cryo-electron microscopy structures: SARS-CoV-2 spike-protein mutations as a test case. European Biophysics Journal, 2022, 51, 555-568.	2.2	4
1106	Role for N-glycans and calnexin-calreticulin chaperones in SARS-CoV-2 Spike maturation and viral infectivity. Science Advances, 2022, 8, .	10.3	10
1107	Mechanosensing view of SARS-CoV-2 infection by a DNA nano-assembly. Cell Reports Physical Science, 2022, 3, 101048.	5.6	9
1108	SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility. Frontiers in Medical Technology, 0, 4, .	2.5	6
1109	Genomic and structural mechanistic insight to reveal the differential infectivity of omicron and other variants of concern. Computers in Biology and Medicine, 2022, 150, 106129.	7.0	6
1111	SARS-CoV-2 from COVID-19 Patients in the Republic of Moldova: Whole-Genome Sequencing Results. Viruses, 2022, 14, 2310.	3.3	1
1112	Cell Entry and Unusual Replication of SARS-CoV-2. Current Drug Targets, 2022, 23, 1539-1554.	2.1	1
1113	De novo selected hACE2 mimics that integrate hotspot peptides with aptameric scaffolds for binding tolerance of SARS-CoV-2 variants. Science Advances, 2022, 8, .	10.3	9
1114	Atomistic insights into the binding of SARS-CoV-2 spike receptor binding domain with the human ACE2 receptor: The importance of residue 493. Journal of Molecular Graphics and Modelling, 2023, 118, 108360.	2.4	5
1115	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. Journal of Pharmaceutical Analysis, 2023, 13, 1-10.	5.3	1
1116	Development of SARS-CoV-2 animal vaccines using a stable and efficient NDV expression system. Journal of Medical Virology, 2023, 95, .	5.0	2
1117	Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike. Journal of Virology, 2022, 96, .	3.4	5
1118	Variation analysis of SARS-CoV-2 complete sequences from Iran. Future Virology, 0, , .	1.8	0
1119	A core epitope targeting antibody of SARS-CoV-2. Protein and Cell, 0, , .	11.0	0
1120	Quantum tunnelling in the context of SARS-CoV-2 infection. Scientific Reports, 2022, 12, .	3.3	1
1121	Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection. Frontiers in Pharmacology, 0, 13, .	3.5	3
1122	SARS-CoV-2 variants of concern and spike protein mutational dynamics in a Swedish cohort during 2021, studied by Nanopore sequencing. Virology Journal, 2022, 19, .	3.4	5

#	ARTICLE	IF	CITATIONS
1123	Synthesis, Processing, and Function of N-Glycans in N-Glycoproteins. <i>Advances in Neurobiology</i> , 2023, , 65-93.	1.8	3
1124	A proteome-scale map of the SARS-CoV-2“human contactome. <i>Nature Biotechnology</i> , 2023, 41, 140-149.	17.5	29
1125	Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	5
1126	Electrochemical Aptasensing of SARS-CoV-2 Based on Triangular Prism DNA Nanostructures and Dumbbell Hybridization Chain Reaction. <i>Analytical Chemistry</i> , 2022, 94, 14755-14760.	6.5	19
1127	Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12267.	4.1	9
1128	Perspective Chapter: Emerging SARS-CoV-2 Variants of Concern (VOCs) and Their Impact on Transmission Rate, Disease Severity and Breakthrough Infections. <i>Infectious Diseases</i> , 0, , .	4.0	0
1129	Genetic diversity and evolutionary convergence of cryptic SARS- CoV-2 lineages detected via wastewater sequencing. <i>PLoS Pathogens</i> , 2022, 18, e1010636.	4.7	32
1130	Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation. <i>Chemico-Biological Interactions</i> , 2022, 368, 110244.	4.0	4
1131	Derivatization of sialylated glycopeptides plus based sialoglycopeptides enrichment using cation exchange media. <i>Analytica Chimica Acta</i> , 2022, 1233, 340492.	5.4	1
1132	Characterization and Function of Glycans on the Spike Proteins of SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	8
1133	One-by-one single-molecule counting method for digital quantification of SARS-CoV-2 RNA. <i>Nano Today</i> , 2022, 47, 101664.	11.9	3
1134	Novel coronavirus mutations: Vaccine development and challenges. <i>Microbial Pathogenesis</i> , 2022, 173, 105828.	2.9	7
1135	Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides. <i>Antiviral Research</i> , 2022, 208, 105445.	4.1	9
1136	Molecular dynamics simulations of the spike trimeric ectodomain of the SARS-CoV-2 Omicron variant: structural relationships with infectivity, evasion to immune system and transmissibility. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 9326-9343.	3.5	4
1137	Efficient Tracing of the SARS-CoV-2 Omicron Variants in Santa Barbara County Using a Rapid Quantitative Reverse Transcription PCR Assay. <i>Diagnostics</i> , 2022, 12, 2805.	2.6	2
1138	Genome characterization, phylogenomic assessment and spatio-temporal dynamics study of highly mutated BA variants from India. <i>Indian Journal of Medical Microbiology</i> , 2022, , .	0.8	1
1139	Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. <i>IScience</i> , 2022, 25, 105507.	4.1	10
1140	Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach. <i>Molecules</i> , 2022, 27, 7522.	3.8	5

#	ARTICLE	IF	CITATIONS
1141	Structural effects of spike protein D614G mutation in SARS-CoV-2. Biophysical Journal, 2023, 122, 2910-2920.	0.5	11
1142	Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection. Heliyon, 2022, 8, e11676.	3.2	4
1143	Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity. PLoS ONE, 2022, 17, e0277745.	2.5	4
1145	Deep Learning Based NLP Embedding Approach for Biosequence Classification. Lecture Notes in Computer Science, 2022, , 161-173.	1.3	2
1146	Identification of an immunogenic epitope and protective antibody against the furin cleavage site of SARS-CoV-2. EBioMedicine, 2023, 87, 104401.	6.1	0
1147	Aero-manufacture of nanobulges for an in-place anticoronaviral on air filters. Journal of Hazardous Materials, 2023, 445, 130458.	12.4	1
1148	SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis. JMIR Bioinformatics and Biotechnology, 0, 4, e42700.	0.9	2
1150	Structural Profiles of SARS-CoV-2 Variants in India. Current Microbiology, 2023, 80, .	2.2	4
1151	Detection of SARS-CoV-2 and Variants in Hospital Wastewater in a Developing Country. Water (Switzerland), 2022, 14, 3798.	2.7	3
1152	Pre-processing SARS-CoV-2 Sequence Data for Application of Machine Learning Techniques for Visualization and Clustering of Virus Characteristics. , 2022, , .		0
1153	SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy. Biomolecules, 2022, 12, 1742.	4.0	6
1155	Distribution of intra-host variations and mutations in the genomes of SARS-CoV-2 and their implications on detection and therapeutics. MedComm, 2022, 3, .	7.2	2
1156	Inferring selection effects in SARS-CoV-2 with Bayesian Viral Allele Selection. PLoS Genetics, 2022, 18, e1010540.	3.5	8
1157	Rapid Point-of-Care Assay by SERS Detection of SARS-CoV-2 Virus and Its Variants. Analytical Chemistry, 2022, 94, 17795-17802.	6.5	12
1158	Supramolecular filaments for concurrent ACE2 docking and enzymatic activity silencing enable coronavirus capture and infection prevention. Matter, 2023, 6, 583-604.	10.0	6
1159	Genomic analysis of SARS-CoV-2 variants of concern circulating in Hawai'i to facilitate public-health policies. PLoS ONE, 2022, 17, e0278287.	2.5	0
1160	The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant. IScience, 2022, 25, 105720.	4.1	27
1161	The SARS-CoV-2 Delta (B.1.617.2) variant with Spike N501Y mutation in the shadow of Omicron emergence. Heliyon, 2022, , e12650.	3.2	0

#	ARTICLE	IF	CITATIONS
1162	Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein. Scientific Reports, 2022, 12, .	3.3	11
1163	Containment of SARS-CoV-2 Delta strain in Guangzhou, China by quarantine and social distancing: a modelling study. Scientific Reports, 2022, 12, .	3.3	2
1164	Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. Scientific Reports, 2022, 12, .	3.3	5
1165	Cross-reaction of current available SARS-CoV-2 MAbs against the pangolin-origin coronavirus GX/P2V/2017. Cell Reports, 2022, 41, 111831.	6.4	2
1166	Mutations in SARS-CoV-2 structural proteins: a global analysis. Virology Journal, 2022, 19, .	3.4	30
1167	Retrospective in silico mutation profiling of SARS-CoV-2 structural proteins circulating in Uganda by July 2021: Towards refinement of COVID-19 disease vaccines, diagnostics, and therapeutics. PLoS ONE, 2022, 17, e0279428.	2.5	0
1168	Mixed formulation of mRNA and proteinâ€¢based COVIDâ€¢19 vaccines triggered superior neutralizing antibody responses. MedComm, 2022, 3, .	7.2	1
1169	Genomic Tracking of SARS-CoV-2 Variants in Myanmar. Vaccines, 2023, 11, 6.	4.4	0
1171	Attenuation and Degeneration of SARS-CoV-2 Despite Adaptive Evolution. Cureus, 2023, , .	0.5	0
1172	Mutational analysis of the spike protein of SARS-COV-2 isolates revealed atomistic features responsible for higher binding and infectivity. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	1
1173	A strategy for evaluating potential antiviral resistance to small molecule drugs and application to SARS-CoV-2. Scientific Reports, 2023, 13, .	3.3	6
1174	Characterization and phylogenetic analysis of Iranian SARSâ€¢CoVâ€¢2 genomes: A phylogenomic study. Health Science Reports, 2023, 6, .	1.5	1
1175	In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations. Bioengineering, 2023, 10, 100.	3.5	10
1176	Structural proteins of SARS-CoV-2. Medical Herald of the South of Russia, 2023, 13, 45-52.	0.4	0
1177	Severe Acute Respiratory Syndrome Coronavirus-2 Delta Variant Study In Vitro and Vivo. Current Issues in Molecular Biology, 2023, 45, 249-267.	2.4	0
1178	Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection. Cell Reports, 2023, 42, 112075.	6.4	5
1180	A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy. PLoS Pathogens, 2023, 19, e1011085.	4.7	5
1182	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. , 2023, , 237-262.		0

#	ARTICLE	IF	CITATIONS
1184	Reverse transcription-loop-mediated isothermal amplification (RT-LAMP) assay as a rapid molecular diagnostic tool for COVID-19 in healthcare workers. <i>Journal of Clinical Virology Plus</i> , 2023, 3, 100134.	1.0	3
1186	Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals. <i>ISME Journal</i> , 2023, 17, 549-560.	9.8	5
1187	Unconventional secretion of unglycosylated ORF8 is critical for the cytokine storm during SARS-CoV-2 infection. <i>PLoS Pathogens</i> , 2023, 19, e1011128.	4.7	11
1188	Modeling the spread dynamics of multiple-variant coronavirus disease under public health interventions: A general framework. <i>Information Sciences</i> , 2023, 628, 469-487.	6.9	4
1189	State of the art in epitope mapping and opportunities in COVID-19. <i>Future Science OA</i> , 2023, 9, .	1.9	4
1190	A bat MERS-like coronavirus circulates in pangolins and utilizes human DPP4 and host proteases for cell entry. <i>Cell</i> , 2023, 186, 850-863.e16.	28.9	23
1192	Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy. <i>Vaccines</i> , 2023, 11, 806.	4.4	1
1193	Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
1194	The SpACE-CCM: A facile and versatile cell culture medium-based biosensor for detection of SARS-CoV-2 spike-ACE2 interaction. <i>Biosensors and Bioelectronics</i> , 2023, 227, 115169.	10.1	0
1195	Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. <i>Heliyon</i> , 2023, 9, e13285.	3.2	4
1197	A Protein Co-Conservation Network Model Characterizes Mutation Effects on SARS-CoV-2 Spike Protein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3255.	4.1	4
1198	Computational Analysis Predicts Correlations among Amino Acids in SARS-CoV-2 Proteomes. <i>Biomedicines</i> , 2023, 11, 512.	3.2	0
1199	Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
1200	Employing T-Cell Memory to Effectively Target SARS-CoV-2. <i>Pathogens</i> , 2023, 12, 301.	2.8	0
1201	Mathematical Modeling of SARS-CoV-2 Omicron Wave under Vaccination Effects. <i>Computation</i> , 2023, 11, 36.	2.0	9
1202	Optimized workplace risk mitigation measures for SARS-CoV-2 in 2022. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
1203	Immunoinformatics Study of SARS-CoV-2 Nucleocapsid Phosphoprotein Identifies Promising Epitopes with Mutational Implications. <i>Moscow University Biological Sciences Bulletin</i> , 2022, 77, 251-257.	0.7	2
1204	Nigelladine A among Selected Compounds from <i>Nigella sativa</i> Exhibits Propitious Interaction with Omicron Variant of SARS-CoV-2: An In Silico Study. <i>International Journal of Clinical Practice</i> , 2023, 2023, 1-14.	1.7	2

#	ARTICLE	IF	CITATIONS
1206	Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
1207	In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing. <i>Journal of Molecular Modeling</i> , 2023, 29, .	1.8	2
1208	Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401.	4.1	4
1209	Epidemiological features, genomic characteristics, and origin tracing of the COVID-19 outbreaks in Beijing from January to September 2022. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	0
1210	Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. <i>Vaccines</i> , 2023, 11, 545.	4.4	3
1211	Nasal sprays for treating COVID-19: a scientific note. <i>Pharmacological Reports</i> , 2023, 75, 249-265.	3.3	10
1212	Rapid Shift from SARS-CoV-2 Delta to Omicron Sub-Variants within a Dynamic Southern U.S. Borderplex. <i>Viruses</i> , 2023, 15, 658.	3.3	3
1213	CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 161, 117000.	11.4	11
1214	Effectiveness of mRNA and viral vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	3
1215	Mutational analysis of catalytic site domain of CCHFV L RNA segment. <i>Journal of Molecular Modeling</i> , 2023, 29, .	1.8	1
1216	A Rapid Method for Generating Infectious SARS-CoV-2 and Variants Using Mutagenesis and Circular Polymerase Extension Cloning. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	5
1217	Immune damage mechanisms of COVID-19 and novel strategies in prevention and control of epidemic. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
1218	ZnO-Based Electrochemical Immunosensor to Assess Vaccine-Induced Antibody-Mediated Immunity against Wild-Type and Gamma SARS-CoV-2 Strains. <i>Biosensors</i> , 2023, 13, 371.	4.7	3
1219	Pseudotyped Viruses for Coronaviruses. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 133-151.	1.6	0
1220	Pseudotyped Viruses for Marburgvirus and Ebolavirus. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 105-132.	1.6	0
1221	Application of Pseudotyped Viruses. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 45-60.	1.6	2
1222	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	10.5	7
1223	Highly Selective Aptamer-Molecularly Imprinted Polymer Hybrids for Recognition of SARS-CoV-2 Spike Protein Variants. <i>Global Challenges</i> , 2023, 7, .	3.6	0

#	ARTICLE	IF	CITATIONS
1224	Myocarditis: causes, mechanisms, and evolving therapies. Expert Opinion on Therapeutic Targets, 2023, 27, 225-238.	3.4	4
1225	Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine. Frontiers in Immunology, 0, 14, .	4.8	1
1226	COVID-19 Wireless Self-Assessment Software for Rural Areas in Nigeria. , 2023, , 213-222.		0
1227	A high-resolution melt curve toolkit to identify lineage-defining SARS-CoV-2 mutations. Scientific Reports, 2023, 13, .	3.3	0
1228	In Silico Analysis of SARS-CoV-2 Spike Proteins of Different Field Variants. Vaccines, 2023, 11, 736.	4.4	1
1229	A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge. Scientific Reports, 2023, 13, .	3.3	2
1230	Enhanced Interfacial H-Bond Networks Promote Glycanâ€“Glycan Recognition and Interaction. ACS Applied Materials & Interfaces, 2023, 15, 17592-17600.	8.0	0
1231	Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. Journal of Biomolecular Structure and Dynamics, 2023, 41, 15207-15218.	3.5	1
1232	A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB. Vaccines, 2023, 11, 778.	4.4	1
1233	Germline-encoded amino acidâ€“binding motifs drive immunodominant public antibody responses. Science, 2023, 380, .	12.6	28
1234	Identification of B-Cell Linear Epitopes in the Nucleocapsid (N) Protein B-Cell Linear Epitopes Conserved among the Main SARS-CoV-2 Variants. Viruses, 2023, 15, 923.	3.3	3
1235	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
1236	High-Affinity Neutralizing DNA Aptamers against SARS-CoV-2 Spike Protein Variants. Covid, 2023, 3, 520-542.	1.5	2
1237	Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. Communications Biology, 2023, 6, .	4.4	0
1238	High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2. Cell Discovery, 2023, 9, .	6.7	2
1239	Potent immunogenicity and broad-spectrum protection potential of microneedle array patch-based COVID-19 DNA vaccine candidates encoding dimeric RBD chimera of SARS-CoV and SARS-CoV-2 variants. Emerging Microbes and Infections, 2023, 12, .	6.5	3
1240	Efficacy of Plant-Made Human Recombinant ACE2 against COVID-19 in a Golden Syrian Hamster Model. Viruses, 2023, 15, 964.	3.3	0
1241	Generation and Functional Analysis of Defective Viral Genomes during SARS-CoV-2 Infection. MBio, 2023, 14, .	4.1	5

#	ARTICLE	IF	CITATIONS
1242	Discovery of Highly Potent Small Molecule Pan-Coronavirus Fusion Inhibitors. <i>Viruses</i> , 2023, 15, 1001.	3.3	1
1243	SARS-CoV-2 Omicron Specific Mutations Affecting Infectivity, Fusogenicity, and Partial TMPRSS2-Independency. <i>Viruses</i> , 2023, 15, 1129.	3.3	3
1244	Newly Characterized Porcine Epidemic Diarrhea Virus GII Subtype Strain. <i>Transboundary and Emerging Diseases</i> , 2023, 2023, 1-14.	3.0	0
1245	Mutations of SARS-CoV-2 and their impact on disease diagnosis and severity. <i>Informatics in Medicine Unlocked</i> , 2023, 39, 101256.	3.4	5
1248	Recent advances in the detection of pathogenic microorganisms and toxins based on field-effect transistor biosensors. <i>Critical Reviews in Food Science and Nutrition</i> , 0, , 1-30.	10.3	1
1249	Electrical Detection Assay Based on Programmable Nucleic Acid Probe for Efficient Single-Nucleotide Polymorphism Identification. <i>ACS Sensors</i> , 2023, 8, 2096-2104.	7.8	6
1250	CoVEffect: interactive system for mining the effects of SARS-CoV-2 mutations and variants based on deep learning. <i>GigaScience</i> , 2022, 12, .	6.4	2
1251	Coding-Complete Genome Sequences of an Omicron Subvariant (BA.5.2.20) of SARS-CoV-2. <i>Microbiology Resource Announcements</i> , 2023, 12, .	0.6	0
1252	Medical Perspective on COVID-19. <i>Contributions To Economics</i> , 2023, , 15-103.	0.3	0
1253	Multivalent IgM scaffold enhances the therapeutic potential of variant-agnostic ACE2 decoys against SARS-CoV-2. <i>MAbs</i> , 2023, 15, .	5.2	3
1254	Human SARS CoV-2 spike protein mutations in West Africa. <i>Health Sciences Investigations Journal</i> , 2023, , 443-447.	0.2	1
1255	Comparative Analysis of SARS-CoV-2 Variants Across Three Waves in India. , 2023, , 104-118.		0
1256	Persistence of SARS-CoV-2 IgG Antibody Response among South African Adults: A Prospective Cohort Study. <i>Vaccines</i> , 2023, 11, 1068.	4.4	1
1257	Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	10
1258	A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines. <i>Heliyon</i> , 2023, 9, e16813.	3.2	0
1259	Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex. <i>MAbs</i> , 2023, 15, .	5.2	3
1260	Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1. <i>Emerging Microbes and Infections</i> , 2023, 12, .	6.5	7
1261	Structure and antigenicity of divergent Henipavirus fusion glycoproteins. <i>Nature Communications</i> , 2023, 14, .	12.8	6

#	ARTICLE	IF	CITATIONS
1262	The proximity-enabled sulfur fluoride exchange reaction in the protein context. Chemical Science, 2023, 14, 7913-7921.	7.4	2
1263	Evolution of Sequence and Structure of SARS-CoV-2 Spike Protein: A Dynamic Perspective. ACS Omega, 0, , .	3.5	1
1264	Development of a Bioluminescent Imaging Mouse Model for SARS-CoV-2 Infection Based on a Pseudovirus System. Vaccines, 2023, 11, 1133.	4.4	1
1265	Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2. Analytical and Bioanalytical Chemistry, 2023, 415, 4779-4793.	3.7	4
1266	Secure reversal of immune evasion from refractory <scp>NSCLC</scp> and highly contagious <scp>CoV</scp> mutants by using <scp>3D</scp> engineered multifunctional biologics. Bioengineering and Translational Medicine, 2023, 8, .	7.1	0
1267	Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination. IScience, 2023, 26, 107208.	4.1	0
1268	The Influence of Different SARS-CoV-2 Strains on Changes in Maximal Oxygen Consumption, Ventilatory Efficiency and Oxygen Pulse of Elite Athletes. Diagnostics, 2023, 13, 1574.	2.6	0
1270	Enhancing SARS-CoV-2 Surveillance through Regular Genomic Sequencing in Spain: The RELECOV Network. International Journal of Molecular Sciences, 2023, 24, 8573.	4.1	1
1272	Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants. Biochemistry, 2023, 62, 2055-2064.	2.5	3
1273	Charting and tracking the evolution of the SARS CoV-2 coronavirus variants of concern with protein mass spectrometry. Analyst, The, 2023, 148, 2834-2843.	3.5	2
1274	Comparative analysis and identification of spike mutations in Iranian COVID-19 samples from the first three waves of disease. Advanced Biomedical Research, 2023, 12, 153.	0.5	0
1276	The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution. Heliyon, 2023, 9, e17701.	3.2	1
1277	Infection and Vaccine Induced Spike Antibody Responses Against SARS-CoV-2 Variants of Concern in COVID-19-Naïve Children and Adults. Journal of Clinical Immunology, 0, , .	3.8	0
1278	Development of extension-mediated self-folding isothermal amplification technology for SARS-CoV-2 diagnosis. Biosensors and Bioelectronics, 2023, 237, 115516.	10.1	2
1279	Probing the binding nature and stability of highly transmissible mutated variant alpha to omicron of SARS-CoV-2 RBD with ACE2 via molecular dynamics simulation. Journal of Cellular Biochemistry, 2023, 124, 1115-1134.	2.6	0
1280	Differential Transcriptomic Landscapes of SARS-CoV-2 Variants in Multiple Organs from Infected Rhesus Macaques. Genomics, Proteomics and Bioinformatics, 2023, , .	6.9	1
1281	Comparison of Sequencing and Phylogenetic Analysis of SARS-CoV-2 Spike Proteins Extracted from Patients and Travelers in Duhok-Iraq. Jundishapur Journal of Microbiology, 2023, 16, .	0.5	0
1282	Cryo-EM and cryo-ET of the spike, virion, and antibody neutralization of SARS-CoV-2 and VOCs. Current Opinion in Structural Biology, 2023, 82, 102664.	5.7	1

#	ARTICLE	IF	CITATIONS
1283	Natural selection shapes the evolution of SARS-CoV-2 Omicron in Bangladesh. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	0
1284	Development of a novel bispecific antibody GR1801 for rabies. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	0
1285	Antigenic evolution of SARS coronavirus 2. <i>Current Opinion in Virology</i> , 2023, 62, 101349.	5.4	12
1286	A Comprehensive Analysis of Structural and Functional Changes Induced by SARS-CoV-2 Spike Protein Mutations. <i>Covid</i> , 2023, 3, 1454-1472.	1.5	2
1287	Effects of the glycosylation of the receptor binding domain (RBD dimer)-based Covid-19 vaccine (ZF2001) on its humoral immunogenicity and immunoreactivity. <i>International Journal of Biological Macromolecules</i> , 2023, 253, 126874.	7.5	0
1288	Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial. <i>BMJ, The</i> , 0, , e070464.	6.0	2
1289	Deep Drug Discovery of Mac Domain of SARS-CoV-2 (WT) Spike Inhibitors: Using Experimental ACE2 Inhibition TR-FRET Assay, Screening, Molecular Dynamic Simulations and Free Energy Calculations. <i>Bioengineering</i> , 2023, 10, 961.	3.5	0
1290	Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2. <i>Vaccine</i> , 2023, 41, 6025-6035.	3.8	0
1291	The Effect of Select SARS-CoV-2 N-Linked Glycan and Variant of Concern Spike Protein Mutations on C-Type Lectin-Receptor-Mediated Infection. <i>Viruses</i> , 2023, 15, 1901.	3.3	1
1292	Neutron reflection and scattering in characterising peptide assemblies. <i>Advances in Colloid and Interface Science</i> , 2023, 322, 103033.	14.7	0
1293	Role of cellular fatty acids in combating the corona virus. , 2023, , 439-453.		0
1294	SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication. <i>Journal of Clinical Medicine</i> , 2023, 12, 6079.	2.4	1
1297	Genome sequencing of SARS-CoV-2 omicron variants in Delhi reveals alterations in immunogenic regions in spike glycoprotein. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
1298	Taking stock of the mutations in human SARS-CoV-2 spike proteins: From early days to nearly the end of COVID-19 pandemic. <i>Current Research in Structural Biology</i> , 2023, 6, 100107.	2.2	0
1299	Contemporaneous SARS-CoV-2-Neutralizing Antibodies Mediated by N-glycan Shields. <i>Viruses</i> , 2023, 15, 2079.	3.3	0
1300	Development of highly sensitive one-step reverse transcription-quantitative PCR for SARS-CoV-2 detection in wastewater. <i>Science of the Total Environment</i> , 2024, 907, 167844.	8.0	6
1302	Some common deleterious mutations are shared in SARS-CoV-2 genomes from deceased COVID-19 patients across continents. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
1303	Effects of N-glycan modifications on spike expression, virus infectivity, and neutralization sensitivity in ancestral compared to Omicron SARS-CoV-2 variants. <i>PLoS Pathogens</i> , 2023, 19, e1011788.	4.7	1

#	ARTICLE	IF	CITATIONS
1304	Development of an Optimized Process for Functional Recombinant SARS-CoV-2 Spike S1 Receptor-Binding Domain Protein Produced in the Baculovirus Expression Vector System. Tropical Medicine and Infectious Disease, 2023, 8, 501.	2.3	0
1305	Structural understanding of SARS-CoV-2 virus entry to host cells. Frontiers in Molecular Biosciences, 0, 10, .	3.5	0
1306	Structural and pKa Estimation of the Amphipathic HR1 in SARS-CoV-2: Insights from Constant pH MD, Linear vs. Nonlinear Normal Mode Analysis. International Journal of Molecular Sciences, 2023, 24, 16190.	4.1	0
1307	Evolutionary trajectory of SARS-CoV-2 genome shifts during widespread vaccination and emergence of Omicron variant. , 2023, 1, .		1
1308	Antiviral Effects of Secondary Metabolites from Jatropha podagrica Leaves against the Pseudotyped Virus of SARS-CoV-2 Omicron. Plants, 2023, 12, 3942.	3.5	0
1309	Impact of SARS-CoV-2 infection on patients with systemic lupus erythematosus in England prior to vaccination: a retrospective observational cohort study. BMJ Open, 2023, 13, e071072.	1.9	0
1310	COV2Var, a function annotation database of SARS-CoV-2 genetic variation. Nucleic Acids Research, 2024, 52, D701-D713.	14.5	2
1311	Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant. Journal of Microbiology and Biotechnology, 2023, , .	2.1	0
1312	Mutation Interest in the Receptor-Binding Domain of Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2 in the Northwest of Iran. Jundishapur Journal of Microbiology, 2023, 16, .	0.5	1
1313	Research on Variation of Sars-Cov-2 and Rapid Detection. , 2023, , .		0
1314	Evolution of SARS-CoV-2 Spikes shapes their binding affinities to animal ACE2 orthologs. Microbiology Spectrum, 2023, 11, .	3.0	0
1315	A potent neutralizing nanobody targeting a unique epitope on the receptor-binding domain of SARS-CoV-2 spike protein. Virology, 2024, 589, 109925.	2.4	0
1318	mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection. IScience, 2023, 26, 108572.	4.1	2
1319	Deciphering the rule of antigen-antibody amino acid interaction. Frontiers in Immunology, 0, 14, .	4.8	0
1320	Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance. Antimicrobial Agents and Chemotherapy, 2024, 68, .	3.2	3
1322	COVID-19: From emerging variants to vaccination. Cytokine and Growth Factor Reviews, 2023, , .	7.2	1
1323	Early Emerging SARS-CoV-2 Spike Mutants Are Diversified in Virologic Properties but Elicit Compromised Antibody Responses. Viruses, 2023, 15, 2401.	3.3	0
1324	Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature, 2023, 624, 630-638.	27.8	4

#	ARTICLE	IF	CITATIONS
1325	The Antiviral Activity of the Lectin Griffithsin against SARS-CoV-2 Is Enhanced by the Presence of Structural Proteins. <i>Viruses</i> , 2023, 15, 2452.	3.3	0
1326	Spike-Seq: An amplicon-based high-throughput sequencing approach for the sensitive detection and characterization of SARS-CoV-2 genetic variations in environmental samples. <i>Science of the Total Environment</i> , 2024, 914, 169747.	8.0	0
1327	Modeling Mutation-Driven Emergence of Drug-Resistance: A Case Study of SARS-CoV-2. <i>Fields Institute Communications</i> , 2023, , 161-174.	1.3	0
1328	Studying SARS-CoV-2 interactions using phage-displayed receptor binding domain as a model protein. <i>Scientific Reports</i> , 2024, 14, .	3.3	0
1329	Rational prediction of immunogenicity clustering through cross-reactivity analysis of thirteen SARS-CoV-2 variants. <i>Journal of Medical Virology</i> , 2024, 96, .	5.0	0
1330	TRIM28-mediated nucleocapsid protein SUMOylation enhances SARS-CoV-2 virulence. <i>Nature Communications</i> , 2024, 15, .	12.8	0
1331	Mutations accumulated in the Spike of SARS-CoV-2 Omicron allow for more efficient counteraction of the restriction factor BST2/Tetherin. <i>PLoS Pathogens</i> , 2024, 20, e1011912.	4.7	2
1332	SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity. <i>MBio</i> , 2024, 15, .	4.1	0
1334	Comparison of analytical performance and economic value of two biosurveillance methods for tracking SARS-COV-2 variants of concern. <i>Microbiology Spectrum</i> , 2024, 12, .	3.0	0
1336	Identifying novel inhibitors targeting Exportin-1 for the potential treatment of COVID-19. <i>Archives of Microbiology</i> , 2024, 206, .	2.2	0
1337	Sequence analysis of the Spike, RNA-dependent RNA polymerase, and protease genes reveals a distinct evolutionary pattern of SARS-CoV-2 variants circulating in Yogyakarta and Central Java provinces, Indonesia. <i>Virus Genes</i> , 2024, 60, 105-116.	1.6	0
1338	Divergent pathogenetic outcomes in BALB/c mice following Omicron subvariant infection. <i>Virus Research</i> , 2024, 341, 199319.	2.2	0
1339	Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant. <i>Cells</i> , 2024, 13, 203.	4.1	0
1340	What makes SARS-CoV-2 unique? Focusing on the spike protein. <i>Cell Biology International</i> , 2024, 48, 404-430.	3.0	0
1341	A Mechanistic Understanding of the Modes of Ca ²⁺ Ion Binding to the SARS-CoV-1 Fusion Peptide and Their Role in the Dynamics of Host Membrane Penetration. <i>ACS Infectious Diseases</i> , 2024, 10, 398-411.	3.8	0
1342	Rapid Profiling of the Glycosylation Effects on the Binding of SARS-CoV-2 Spike Protein to Angiotensin-Converting Enzyme 2 Using MALDI-MS with High Mass Detection. <i>Analytical Chemistry</i> , 2024, 96, 1898-1905.	6.5	0
1344	Stabilization of the Metastable Pre-Fusion Conformation of the SARS-CoV-2 Spike Glycoprotein through N-Linked Glycosylation of the S2 Subunit. <i>Viruses</i> , 2024, 16, 223.	3.3	0
1345	A Data Analytics-Based Study in SARS-CoV-2 Genome Revealed a Commonality in the Infection Pattern. <i>Lecture Notes in Electrical Engineering</i> , 2024, , 173-184.	0.4	0

#	ARTICLE	IF	CITATIONS
1347	A mouse xenograft long-term replication yields a SARS-CoV-2 Delta mutant with increased lethality. Journal of Medical Virology, 2024, 96, .	5.0	0
1349	Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein. Journal of Infection, 2024, 88, 106121.	3.3	0
1350	Relationship between the Viral Load in Patients with Different COVID-19 Severities and SARS-CoV-2 Variants. Microorganisms, 2024, 12, 428.	3.6	0
1351	Incipient functional SARS-CoV-2 diversification identified through neural network haplotype maps. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121, .	7.1	0
1352	Rapid simulation of glycoprotein structures by grafting and steric exclusion of glycan conformer libraries. Cell, 2024, 187, 1296-1311.e26.	28.9	0
1353	Sequence signatures within the genome of SARS-CoV-2 can be used to predict host source. Microbiology Spectrum, 2024, 12, .	3.0	0
1354	N-glycosylation of the SARS-CoV-2 spike protein at Asn331 and Asn343 is involved in spike-ACE2 binding, virus entry, and regulation of IL-6. Microbiology and Immunology, 2024, 68, 165-178.	1.4	0
1355	A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant. Journal of Medical Virology, 2024, 96, .	5.0	0
1356	Predicting Natural Evolution in the RBD Region of the Spike Glycoprotein of SARS-CoV-2 by Machine Learning. Viruses, 2024, 16, 477.	3.3	0
1358	Screening Peptide Drug Candidates To Neutralize Whole Viral Agents: A Case Study with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). ACS Pharmacology and Translational Science, 2024, 7, 1032-1042.	4.9	0
1359	Influence of Mutations and N-Glycosylation Sites in the Receptor-Binding Domain (RBD) and the Membrane Protein of SARS-CoV-2 Variants of Concern on Antibody Binding in ELISA. Biology, 2024, 13, 207.	2.8	0
1360	Whole-Genome Sequencing and Mutation Analyses of SARS-CoV-2 Isolates from Indonesia. Pathogens, 2024, 13, 279.	2.8	0
1361	A long-term cohort study: the immune evasion and decreasing neutralization dominated the SARS-CoV-2 breakthrough infection. Frontiers in Cellular and Infection Microbiology, 0, 14, .	3.9	0
1362	Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1. Viruses, 2024, 16, 473.	3.3	0